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ABSTRACT 
Opioid analgesics are effective in relieving acute and chronic pain. 
However, adverse effects and the development of opioid dependence and 
tolerance may restrict the use of opioids and result in inadequate pain 
relief. The effects of four structurally and functionally different drugs 
already on the market, ibudilast, atipamezole, spironolactone, and 
ketamine, were studied in coadministration with morphine, the 
prototypical mu-opioid receptor agonist. Experiments were conducted 
using thermal and mechanical tests of nociception in male Sprague-
Dawley rats. Morphine tolerance was produced during four days by 
subcutaneous or intrathecal delivery of morphine. Drug and metabolite 
concentrations were measured using high-pressure liquid 
chromatography-tandem mass spectrometry. The objective of the thesis 
study was to search for potential drugs to augment morphine 
antinociception and prevent opioid tolerance. 
Ibudilast, a phosphodiesterase and macrophage inhibitory factor 
inhibitor, had transient sedative effects, but it restored the antinociceptive 
effect of morphine in morphine-tolerant rats after single and repeated 
administration. It did not prevent the development of opioid tolerance.  
Atipamezole, an alpha-2-adrenoceptor antagonist used for the 
reversal of sedation in animals during anesthesia, was effective in 
augmenting intrathecal morphine antinociception in both opioid-naïve 
and opioid-tolerant animals. These effects were observed at doses lower 
than those required for the antagonism of alpha-2-adrenoceptors. In 
subcutaneous administration, low doses of atipamezole did not influence 
morphine antinociception. 
The mineralocorticoid receptor antagonist spironolactone dose-
dependently enhanced morphine antinociception. This effect was 
mediated via the increased access of morphine to the central nervous 
system by the inhibition of the efflux protein P-glycoprotein. 
Spironolactone did not inhibit the metabolism of morphine to the 
pronociceptive metabolite morphine-3-glucuronide, and it did not prevent 
the development of opioid tolerance. 
The effects of ketamine in augmenting opioid analgesia in tolerance 
are thought to result from a beneficial pharmacodynamic interaction. 
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When acute ketamine was administered to rats under chronic morphine 
treatment, the brain concentrations of morphine, ketamine and 
norketamine were increased compared with the situation where either 
morphine treatment or acute ketamine were administered alone. The 
results indicate a potentially beneficial pharmacokinetic interaction 
between the two drugs. 
The results of the thesis study demonstrate that ibudilast and 
atipamezole modulate nociception at systemic and spinal levels in 
preclinical models of pain, and they may prove advantageous as an 
adjuvant to opioid therapy. Spironolactone had a pharmacokinetic 
interaction with morphine, leading to increased morphine concentrations 
in the central nervous system. Ketamine, a drug used for the treatment of 
opioid tolerance in cancer patients, may undergo previously unrecognized 
beneficial pharmacokinetic interactions with morphine. 
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1. INTRODUCTION 
The treatment of acute and chronic severe pain remains a major challenge. 
Opioids, such as morphine and oxycodone, are used as primary analgesics in 
moderate to severe pain (Hoskin, 2008; Kalso et al., 2004). However, long-term 
opioid treatment, in particular, has several problems, such as the development of 
tolerance and dependence with withdrawal symptoms. Tolerance is manifested 
as a need to increase the opioid dose to reach an equipotent analgesic effect, 
whereas opioid-induced hyperalgesia is a process of sensitization in which 
opioids cause hypersensitivity to painful stimuli. Dose escalation of opioids is 
typically limited by adverse effects such as respiratory depression, nausea, and 
constipation (McNicol et al., 2003). The adverse effects and tolerance with 
hyperalgesia may necessitate the discontinuation of opioid treatment and result 
in inadequate pain control. 
The classic models for explaining the development of opioid tolerance and 
hyperalgesia have mostly focused on cellular and network changes in neurons 
themselves. The changes caused by repeated administration of opioids and 
consequent opioid receptor activation may involve adaptive changes in the 
neurons, such as the internalization of opioid receptors (Zuo, 2005), 
upregulation of N-methyl-D-aspartate receptor function (Mao et al., 2002; 
Shimoyama et al., 2005),  production of nitric oxide, or down-regulation of 
glutamate transporters (Pasternak, 2007). Moreover, a counter-regulatory 
antiopioid system could be involved, including neuromodulators such as 
cholecystokinin or dynorphin (Xie et al., 2005). The formation of heterodimeric 
receptor complexes between mu-opioid and other receptors, such as the alpha-2-
adrenoceptor, may modulate the function of the mu-opioid–receptor coupled 
effectors and the efficacy of opioids (Jordan et al., 2003). 
Recent studies suggest that opioid administration may also induce 
tolerance via mechanisms other than those involving neurons. The glial cells of 
the central nervous system (CNS) have previously been considered as 
neuroimmune cells that mainly provide support and nutrition for the neurons. 
New data indicate that activated glial cells may modulate the activity of the 
nociceptive neurons in the CNS (Ji et al., 2013; Grace et al., 2014) by releasing 
various proinflammatory substances and actively oppose the analgesic action of 
opioids on pain-transmission neurons (Wang et al., 2012b). Another line of 
opioid tolerance research has focused on the pharmacokinetics of opioids, 
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especially their potentially reduced access to the CNS through the blood–brain 
barrier (BBB) (Mercer and Coop, 2011). Of the known BBB drug transporters, 
morphine is an acknowledged substrate of the efflux transporter P-glycoprotein 
(P-gp) (Letrent et al., 1998; Schinkel et al., 1995; Xie et al., 1999). Upregulation 
of this transporter by opioids could lead to decreased access of opioids to the 
brain and compromised analgesia. However, limited knowledge exists 
concerning other potential opioid-transporting proteins and pharmacokinetic 
drug–drug interactions between analgesics. 
The present investigations were conducted to acquire further information 
on possible adjuvant drugs that could improve the efficacy of opioids in acute 
and chronic treatment, with particular emphasis on both pharmacodynamic and 
pharmacokinetic interactions. 
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2. REVIEW OF THE LITERATURE 
2.1 Physiology of nociception and pain 
2.1.1 Primary nociceptors 
Somatosensation includes several submodalities, including touch (detection of 
light mechanical stimuli), proprioception (detection of mechanical stretch of 
muscles and joints), thermosensation (detection of cold and warmth), and 
nociception (detection of noxious thermal, mechanical, or chemical stimuli), that 
evoke pain sensations (Julius, 2013). Noxious stimuli are initially detected by 
primary afferent sensory nerve fibers that innervate a peripheral target. This 
information is transmitted to secondary afferent dorsal horn neurons in the 
spinal cord and further to the brain via ascending neural circuits. The cell bodies 
of primary afferent sensory nerves, referred to as nociceptors, lie in the dorsal 
root ganglia (DRG) for the body and the trigeminal ganglion for the face. They 
have a peripheral and a central axon innervating the target organ and the spinal 
cord, respectively. The nociceptors only discharge action potentials when they 
are stimulated to a noxious range, indicating that they are only capable of 
detecting and responding to potentially injurious stimuli (Todd and Koerber, 
2013). 
Nociceptors are divided into two major classes: 1) medium-diameter 
myelinated A-delta fibers that convey acute, fast pain and 2) small-diameter 
unmyelinated C fibers that convey poorly localized, slow pain. C fibers are 
usually divided into peptidergic and nonpeptidergic neurons. Peptidergic 
neurons may contain substance P and calcitonin gene-related peptide (CGRP) 
and express the nerve growth factor receptor TrkA. The nonpeptidergic 
population expresses the c-Ret neurotrophin receptor with glial-derived 
neurotrophic factor as its agonist. They usually lack substance P and CGRP, but 
express purinergic P2X3 and P2Y1 receptors. The large-diameter A-beta fibers 
are rapidly conducting primary afferent nerves that do not convey nociceptive 
information. However, their activity may modulate pain perception by activating 
inhibitory interneurons in the spinal cord (Todd and Koerber, 2013). 
Review of the literature 
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2.1.2 Nociception at the spinal cord level 
The dorsal horn of the spinal cord is organized into histologically and 
functionally distinct laminae. They receive their input by the primary afferent 
nerve fibers. A-delta fibers generally project to lamina I and also to the deep 
lamina V, whereas the C fibers project to the superficial laminae I and II, with 
some terminals in deeper laminae (Fig. 1A). The A-beta fibers, mediating light 
touch, project to laminae III, IV and V (Basbaum et al., 2009; Todd and 
Koerber, 2013). In addition to the primary afferent nerves and projection 
neurons, one-third of the neuron population consists of inhibitory interneurons 
using gamma-amino butyric acid (GABA) and/or glycine as neurotransmitters. 
Inhibition at the spinal cord level is an important form of endogenous pain 
control. For example, in the absence of sensory stimuli, the release of tonic 
inhibitory neurotransmitter inhibits spontaneous discharges of the spinal dorsal 
horn neurons (for review, see Todd, 2010). 
2.1.3 Nociception and pain in supraspinal structures 
Projection neurons located in laminae I and V are responsible for most of the 
output from the dorsal horn to the supraspinal structures (Basbaum and Jessell, 
2000). The spinothalamic tract, which conveys nociceptive messages to the 
thalamus, is especially relevant for the sensory-discriminative aspects of pain, 
whereas the spinoreticulothalamic tract conveys nociceptive information to the 
brainstem and is more relevant in poorly localized nociception. There are also 
connections to the amygdala via the parabrachial region of the dorsolateral pons. 
This connection has been associated with information related to the 
unpleasantness of the nociceptive stimulus. From these loci, information reaches 
the cortical areas (Fig. 1B). Pain has been suggested to result from the activation 
of numerous structures, with the somatosensory cortex being largely 
responsibility for the sensory-discriminative properties of pain and others, such 
as the anterior cingulate cortex and insular cortex, having responsibility for the 
emotional aspects (Apkarian et al., 2005). The pain matrix concept involves 
several interacting neuronal networks, of which the nociceptive matrix (mainly at 
the posterior insular region), receiving input from the spinothalamic projection, 
is responsible for cortical nociceptive processing. This information is further 
transferred to a second-order network and to perception involving parietal, 
prefrontal, and anterior insular areas (Garcia-Larrea and Peyron, 2013).  
Review of the literature 
16 
 
 
Figure 1. Schematic diagram of the spinal cord dorsal horn (A) and the supraspinal 
structures (B) involved in nociception and pain. PAG, periaqueductal gray; PB, 
parabrachial nucleus; RVM, rostroventral medulla. Adapted from Basbaum et al. 
(2009) and Todd and Koerber (2009). 
 
According to the International Association for the Study of Pain (IASP), pain is 
described as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage”. This 
implies that pain can only be experienced at the whole-organism level. Animals 
cannot verbally report pain, but certain recurrent reactions to nociceptive stimuli 
can be interpreted as nociception. The extrapolation of the analgesic response 
from vastly differing pain models or the use of measures with unclear relevance is 
a problem in animal research. Attempts are being made to develop new specific 
pain measurement methods. For example, a facial expression pain coding system 
for the mouse has recently been introduced (Matsumiya et al., 2012), a system 
similar to those used for evaluating pain in nonverbal human populations. 
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2.1.4 Supraspinal mechanisms of pain modulation 
The relationship between the peripheral noxious stimulation and the perceived 
pain experience depends on many variables, including the behavioral context and 
other sensory inputs. Modification of the pain response results from the action 
of CNS networks. Suppression of the nociceptive reflexes and pain sensation is 
essential in the face of a threat, whereas enhanced pain in tissue inflammation or 
injury may promote sheltering and recuperation. At present, it is widely 
acknowledged that the continuous activation of descending pain facilitator 
networks is a contributor to chronic pain states (Heinricher and Fields, 2013).  
The first evidence for supraspinal sites controlling ascending sensory 
pathways was published in the 1950s, and a specific pain modulatory system 
theory was introduced by Melzack and Wall (1965) in the Gate control theory of 
pain. Descending projections to the spinal cord control spinal nociception either 
directly or through spinal interneurons (Todd, 2010). The discovery of 
periaqueductal gray (PAG) and its central role in the brain mechanisms of pain 
processing was a critical step in understanding the modulation of nociception. 
Simple effects evoked by noxious stimulus at the spinal cord level may be 
inhibited by the stimulation of PAG or its relay in the rostroventral medulla 
(RVM). The major output of the RVM is to the spinal cord via neurons 
including 5-hydroxytryptamine (5-HT), GABA, and several neuropeptides 
(Skagerberg and Björklund, 1985). PAG receives direct projections from sites 
involved in supraspinal pain processing, including the cingulate and insular 
cortex, hypothalamus, and amygdala (Aggleton et al., 1980; Floyd et al., 2000; 
Rizvi et al., 1996).  
The PAG-RVM is crucial for the analgesic actions of opioids and 
endogenous opioid peptides (see 2.2.3). Interestingly, other substances such as 
cannabinoids also partly produce their antinociceptive effect by activating the 
PAG-RVM system. Another important descending modulatory system is the 
pontomedullary noradrenergic pathway, reciprocally linked with the PAG-RVM 
system (see 2.3.4). 
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2.2 Opioids 
2.2.1 Indications and prevalence of opioid therapy in Finland 
Opioids are the most potent analgesic agents used for pain therapy. They are the 
gold standard in the treatment of acute postoperative pain and also severe to 
moderate cancer pain (Caraceni et al., 2012). The usage of opioids in the 
treatment of non-cancer chronic pain has significantly increased. In Finland, 
nine different opioids are currently on the market, grouped into weak (codeine 
and tramadol), intermediate (buprenorphine), and strong (fentanyl, 
hydromorphone, methadone, morphine, oxycodone, and pethidine) categories 
based on their pharmacological efficacy. In 1990, the total consumption of 
opioids was three defined daily doses (DDD) per 1000 inhabitants, increasing to 
a level of 17 DDD per 1000 inhabitants by 2011, indicating a six-fold increase 
in opioid consumption during 20 years. This development goes hand in hand 
with the global development: the use of prescribed opioids increased threefold 
from 1989 to 2009, and the use of morphine worldwide increased from 6.5 tons 
in 1989 to 41.8 tons in 2009 (Huxtable et al., 2011). The majority of opioids 
consumed in Finland are weak opioids, mainly codeine. The consumption of 
morphine has been stable for the last 10 years (0.27 DDD), whereas the 
consumption of oxycodone has increased almost threefold to 0.81 DDD. In 
2011, strong opioids were prescribed to 25 000 outpatients, and the total 
number of inhabitants who had used opioids in 2011 was 410 000. Based on the 
Finnish registries, it is not possible, however, to determine the individual 
consumption for different diagnoses (Nevantaus et al., 2013; summary in 
English). 
2.2.2 Opioid receptors 
Opioid receptors belong to the superfamily of guanine nucleotide-binding 
regulatory protein (G protein) coupled receptors (GPCRs), a family that 
contains several hundred members in the human genome (Lagerström and 
Schiöth, 2008). The receptor contains seven transmembrane domains that are 
connected by short loops. They display an extracellular N-terminal domain and 
an intracellular C-terminal tail. The opioid receptors were first demonstrated in 
the 1970s (Pert and Snyder, 1973), and in the 1990s the opioid receptor family, 
including the classical mu, kappa, and delta receptors, as well as the closely 
related opioid receptor like (ORL) 1 receptor, were cloned and hence 
Review of the literature 
19 
molecularly identified (Taylor and Dickenson, 1998). Mu, delta and kappa 
receptors are highly homologous, with greatest variability within the extracellular 
loops and the N- or C-terminal tails. In 2012, the crystal structure of the kappa 
receptors was determined with X-ray crystallography (Wu et al., 2012), 
representing another milestone in opioid research. Pharmacological activities of 
the prototypal opioid receptor agonists have been tested in mice lacking the mu-, 
delta- or kappa-opioid receptor genes. The results suggest that the mu-opioid 
receptor is responsible for the analgesic activities of morphine (Kieffer and 
Gavériaux-Ruff, 2002) (Fig. 2). 
Mu-opioid receptors are coupled to pertussis toxin-sensitive Gα proteins 
Go and Gi to inhibit the cyclic adenosine monophosphate (cAMP) pathway by 
inhibiting adenylyl cyclase activity (Connor and Christie, 1999; Laugwitz et al., 
1993). By initiating the release of the Gβγ dimer from Gi or Go, opioids reduce 
the opening of voltage-dependent calcium channels (Saegusa et al., 2000) or 
activate inwardly rectifying potassium channels (Ikeda et al., 2000), phenomena 
leading to decreased neuronal excitability and analgesia. Opioids also may 
activate mitogen-activated protein kinase (MAPK) cascades, affecting the 
transcriptome of the cell. 
 
Morphine 
DPDPE 
Deltorphin U50,488H 
Mu Delta Kappa 
Analgesia Reward 
Dependence 
Dysphoria 
Agonist 
Receptor 
Eﬀect 
  
 
Figure 2. Opioid receptor-mediated effects. The main pharmacological activities of 
the opioid receptor agonist prototypes have been assessed in mu-, delta-, and kappa 
knockout mice. Modified from Kieffer and Gavériaux-Ruff (2002). DPDPE, D-
penicillamine(2,5)-enkephalin. 
Review of the literature 
20 
2.2.3 Mechanisms of opioid-induced analgesia 
The actions of opioids in mediating analgesia after systemic administration 
present their actions in both the brain and spinal cord.  
Within the spinal cord, opioid receptors are predominantly located in 
laminae I and II of the dorsal horn, with smaller quantities in deeper layers. The 
contribution of mu, delta, and kappa receptors to opioid binding in the rat spinal 
cord is roughly 70%, 24% and 6%, respectively (Besse et al., 1990; Rahman et al., 
1998). Over 70% of the receptors are located on the central terminals of small-
diameter (mostly C and alpha-delta) primary afferent neurons, implying that the 
main mechanism of spinal opioid analgesia lies in the activation of presynaptic 
opioid receptors, decreasing the release of excitatory transmitters and nociceptive 
transmission. Another confirmation of the presynaptic action is provided by the 
observation that the release of primary afferent transmitters such as substance P 
and CGRP, contained in small afferents, is reduced after opioid administration 
(Go and Yaksh, 1987). Taken together, the capacity of spinal opioids to reduce 
the release of excitatory neurotransmitters and to decrease neuron excitability in 
the dorsal horn is considered to mediate the powerful effects of opioids on 
nociception at the spinal cord level. In humans, there is extensive literature 
indicating the clinical efficacy of spinal opioids (Yaksh, 1997). 
As opioid receptors are synthesized in the DRG cell bodies, they are also 
transported peripherally to the axons. The peripheral application of exogenous 
opioid agonists has only been antinociceptive in inflammatory states (Machelska 
et al., 1999). 
Microinjections of opioids to specific brain sites have demonstrated that 
opioid agonists, in a manner consistent with their activity on the mu-opioid 
receptor, block nociceptive behavior. The supraspinal sites where morphine 
microinjections have shown efficacy are the insular cortex, amygdala, 
hypothalamus, PAG, and RVM. Interest in the PAG-RVM system was raised 
when it was discovered that opioid analgesia is also partly mediated via direct 
post-synaptic hyperpolarization of a neuron subpopulation in this area (Pan et 
al., 1990; Yaksh et al., 1988). On the other hand, RVM may also contribute to 
hyperalgesia and allodynia in inflammatory and neuropathic pain (Porreca et al., 
2002) or prolonged opioid administration (Vanderah et al., 2001). Additionally, 
especially in humans, opioids also have supraspinal mood-altering effects that 
modulate the experience of pain. In addition to relief of distress and increased 
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tolerability of pain, patients may also experience euphoria (Yaksh and Wallace, 
2011). 
2.2.4 Morphine 
Morphine ([5α,6α]-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol) 
(Fig. 3) is the main active substance in opium. As it is difficult to synthesize, it is 
still extracted from poppy straw or obtained from opium. It has become the gold 
standard of opioids against which all other opioids are compared. Its main effect 
is mediated by binding to and activating the mu-opioid receptors in the CNS. 
Morphine is also the prototypical agonist of the mu receptor (Yaksh and 
Wallace, 2011). 
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Figure 3. Structural formula of morphine. 
 
After peroral administration, the absorption of morphine from the 
gastrointestinal tract is modest with a bioavailability of approximately 25%. 
Hence, its first-pass metabolism in the liver and gut wall is significant. In 
parenteral intravenous, intramuscular, and subcutaneous (i.v., i.m., and s.c., 
respectively) administration, the onset of the effects is more rapid and the effect 
of the same dose is larger. Morphine is also available as suppositories with a 
rather good absorption through the rectal mucosa. About one-third of morphine 
in plasma is bound to proteins after a therapeutic dose. The analgesic plasma 
concentration range in patients suffering from cancer is very large, 22–364 
ng/mL (Neumann et al., 1982). 
Morphine is glucuronidated to morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) by uridine diphosphate (UDP)-glucuronosyl 
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transferase 2B7 (UGT2B7) in humans (Coffman et al., 1997), and mostly to 
M3G by Ugt2b1 in rodents (Coffman et al., 1996; King et al., 1997; Pritchard 
et al., 1994). A small amount is metabolized to normorphine via the cytochrome 
P-450 (CYP) system, especially CYPs 3A4 and 2C8 (Projean et al., 2003). In 
humans, after oral morphine administration, the areas under curve (AUC) of 
M6G and M3G exceed that of the parent drug by factors of 9:1 and 50:1, 
respectively (Osborne et al., 1990). Morphine is mainly excreted via the kidney 
in the 3-glucuronide form; very little morphine is excreted unchanged. M6G is 
also excreted by the kidney, and in kidney failure it may accumulate, probably 
explaining the increased and prolonged effect of morphine in this patient group 
(Owen et al., 1983). Some enterohepatic circulation of morphine and its 
glucuronides occurs, which can be seen as traces of morphine in the feces for 
some days after the end of therapy (Walsh and Levine, 1975). 
In rodents, the disposition of morphine in the CNS is modulated by P-gp 
(Letrent et al., 1999; Schinkel et al., 1995; Xie et al., 1999), an efflux protein at 
the blood–brain barrier (BBB). Thus, P-gp inhibition could lead to increased 
access of morphine to the CNS (see 2.3.5). 
2.2.5 Adverse effects of morphine 
Opioid therapy may be compromised by adverse effects (Table 1 and Fig. 4), of 
which most are mediated through the opioid receptors. The severity of these 
adverse effects on the patient may range from mild to severe: constipation is 
common but it may generally be alleviated with pharmacological methods, 
whereas respiratory depression is the most common cause of death associated 
with opioid toxicity (Pattinson, 2008). The risk of respiratory depression in pain 
treatment is lower than in opioid abuse. It has been suggested that the 
respiratory center also receives nociceptive input, and pain thus acts as a 
physiological antagonist for opioid-induced respiratory depression (Hanks and 
Twycross, 1984). Acute potentially dangerous adverse effects of opioids may be 
antagonized with naloxone, the prototypical opioid receptor antagonist, given 
intravenously or subcutaneously. The bioavailability of naloxone is poor, leading 
to minimal systemic concentrations after peroral administration. Interestingly, 
this effect may be advantageous in the treatment of constipation, in which the 
target of opioid receptor antagonism lies in the enteric nervous system of the gut. 
Indeed, oral naloxone and subcutaneous methylnaltrexone are currently in use to 
reverse opioid-induced constipation without compromising analgesia (Leppert, 
2010). 
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Table 1. Possible adverse effects of opioids in chronic pain treatment (Lawlor and 
Bruera, 1998; Schug et al., 1992). 
 
Neuropsychiatric Delirium, sedation, mood changes, anxiety, sleep disturbance 
Neurological Myoclonus, miosis, hyperalgesia, allodynia, seizures 
Gastrointestinal Dry mouth, nausea and vomiting, constipation, biliary spasm 
Respiratory Respiratory depression, pulmonary edema, cough suppression 
Urological Micturitional disturbance 
Dermatological Pruritus, sweating 
Endocrine Hormonal changes, immune changes 
Pharmacological Tolerance, dependence 
 
 
Opioids affect two major hormonal systems: the hypothalamus-pituitary-adrenal 
axis and the hypothalamus-pituitary-gonadal axis. Morphine causes a strong 
decrease in plasma cortisol levels in adults (Banki and Arato, 1987) and 
laboratory animals (Bartolome and Kuhn, 1983; Collu et al., 1976; Rolandi et 
al., 1983). In the gonadal axis, typical changes in hormonal secretion are a 
decrease in luteinizing hormone (LH), follicle-stimulating hormone (FSH), 
testosterone, and estrogen levels, whereas an increase in prolactin levels may be 
observed (Malaivijitnond and Varavudhi, 1998). Effects of opioids on the 
immune system may be mediated through their direct effects on immune cells, 
as opioid-related receptors on immune cells have been discovered (Makman, 
1994), or indirectly via changes in neuroendocrine system. Opioids appear to 
alter both innate and adaptive immune systems (Risdahl et al., 1998; Roy and 
Loh, 1996). Results from in vivo and in vitro studies suggest that prolonged 
opioid exposure is likely to suppress immune function in the periphery (Roy et 
al., 2006; Sacerdote et al., 1997); for a review, see (Ninković and Roy, 2013). 
Interestingly, microglial cells, immune cells of the CNS, have recently gained 
considerable attention in the study of pain (see 2.3.3). 
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Figure 4. Possible adverse effects specific to prolonged opioid therapy (Ballantyne 
and Mao, 2003). 
2.3 Modulation of opioid-induced antinociception 
2.3.1 Opioid tolerance and opioid-induced hyperalgesia 
Opioid tolerance is a pharmacological phenomenon that develops during chronic, 
repeated use of opioids and leads to the need to increase the opioid dose to reach 
an equipotent analgesic effect, i.e. the dose-response curve is shifted to the right. 
Two types of tolerance, associative and non-associative tolerance, can be 
distinguished and they appear to involve different neurotransmitter mechanisms 
(Grisel et al., 1996; Mitchell et al., 2000). Associative tolerance involves 
psychological factors, and they may be clinically connected to non-
pharmacological aspects of patient care, for example admission to the hospital 
ward. Non-associative tolerance occurs at the cellular or organism level and 
involves numerous intracellular changes, as well as changes in the function of 
wider neuronal networks (Grisel et al., 1996). A prevailing theory is that opioid 
tolerance is a complex process that involves multiple regulatory mechanisms 
occurring at the level of both neurons and neuronal networks. Many features of 
opioid tolerance may be seen as a natural attempt of neuronal homeostasis to 
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reach equilibrium, i.e. involving regulatory or opponent processes to overcome 
prolonged activation of opioid receptors. Desensitization, on the other hand, is a 
process referring to the acute loss of mu-opioid receptor and effector coupling 
that occurs within seconds to minutes after the initiation of opioid exposure. 
Both tolerance and desensitization may be used interchangeably to describe the 
loss of receptor activity after chronic treatment. (Williams et al., 2013) 
Tolerance, however, does not necessarily specify the cellular or molecular 
mechanisms that are responsible for the phenomenon.  
Multiple opioid receptor-related phenomena may contribute to cellular 
tolerance. Phosphorylation of the mu-opioid receptor is a widely accepted theory 
of desensitization. Many kinases, e.g. G protein receptor kinase (GRK), c-Jun 
N-terminal kinase (JNK), protein kinases A and C (PKA and PKC), 
Ca2+/calmodulin-dependent protein kinase (CaMKII), and MAPK, may be 
involved in desensitization and receptor endocytosis (Koch and Höllt, 2008). 
The endocytosis pathway does not necessarily lead to receptor degradation, but it 
may also lead to dephosphorylation of the receptor and its replacement on the 
surface of the cell. However, morphine is only a weak stimulator of mu-opioid 
receptor phosphorylation (Zhang et al., 1998). Based on these data, it has been 
speculated that morphine tolerance may not be a result of receptor 
desensitization but rather the lack of desensitization, which may lead to 
prolonged receptor signaling (Whistler and Zastrow, 1998; Williams et al., 
2013). Downregulation of functional mu-opioid receptors is not considered 
relevant for morphine tolerance, as functional binding studies have implied that 
the loss of over 80% of functional mu-opioid receptors is needed to observe a 
rightward shift in the half maximal effective concentration (EC50) of morphine 
(Stafford et al., 2001; Williams et al., 2013). 
The mu-opioid receptor is coupled to cellular effectors such as adenylyl 
cyclase and Ca2+ and K+ channels, affecting the release of neurotransmitters. 
Repeated opioid administration initiates counterregulatory processes in these 
systems, of which the best described is the superactivation of adenylyl cyclase 
and increased intracellular cAMP concentrations. This, in turn, induces PKA 
activation and an increased inward cation current through Ca2+ channels (Bailey 
and Connor, 2005; Collier, 1980). Even though different opioids share the same 
binding site (presumably the mu-opioid receptor) to produce their physiological 
effects, there may be significant differences in the activation of different G 
proteins and intracellular downstream responses. This is called functional 
selectivity or biased agonism; for review, see Raehal et al. (2011). 
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Opioid tolerance not only has receptor- and effector-level effects, but also 
includes system-level counteradaptation. The observed tolerance may result from 
not only pharmacological tolerance, but also enhanced excitability of the opioid-
regulated pathways. Indeed, opioids may initiate a pronociceptive process also 
known as opioid-induced hyperalgesia (OIH). While tolerance at simplest is 
characterized by a progressive decrease in the half maximal effective dose (ED50) 
that can be overcome by increasing the drug dose, OIH is a process of 
sensitization in which opioids cause hypersensitivity to pain (Fishbain et al., 
2012). The relative contributions of these two processes to the observed overall 
decrease in the opioid analgesic effect has not been established, and these 
processes may have mutual intercellular characteristics and contribute in parallel 
to the decrease the clinical efficacy. The common mechanisms may involve 
activation of bulbospinal pathways that increase the secondary neuron 
excitability of the spinal dorsal horn via a counter-regulatory antiopioid system, 
including neuromodulators such as cholecystokinin or dynorphin (Gardell et al., 
2002; Xie et al., 2005). Glutamatergic cellular mechanisms that lead to 
upregulation of N-methyl-D-aspartate (NMDA) receptor function may also 
contribute to OIH (Mao et al., 1994). OIH has been described in rodents 
(Célèrier et al., 2000; Li et al., 2001a; Mao et al., 1994; Vanderah et al., 2001, 
Minville et al., 2010) and pain-free human volunteers receiving opioid infusions 
(Koppert et al., 2003; Luginbühl et al., 2003; Tröster et al., 2006, Vinik and 
Kissin, 1998); for a meta-analysis, see Fishbain et al. (2009). However, data in 
many other settings are contradictory (Fishbain et al., 2009), and there are no 
clinical data on the prevalence of OIH (Lee et al., 2011). During opioid 
maintenance therapy in addicts, a modality-specific increased pain sensitivity has 
been observed in studies with small populations (Compton et al., 2001; 2012; 
Prosser et al., 2008; Doverty et al., 2001). In postoperative studies, OIH has 
mainly been studied after opioid-based anesthesia (Chia et al., 1999; Cooper et 
al., 1997; Guignard et al., 2000; Katz et al., 1996; Lahtinen et al., 2008; 
Schmidt et al., 2007; Schraag et al., 1999; Shin et al., 2010). In a recent meta-
analysis, high intraoperative doses of remifentanil, a potent opioid with a short 
elimination half-life, were associated with a small increase in postoperative pain 
(Fletcher and Martinez, 2014). OIH may also be a clinical problem in chronic 
pain (Hay et al., 2009; Chu et al., 2006; Hooten et al., 2010). In practice, the 
discontinuation of a large dose of morphine and substitution with another opioid 
(opioid rotation) has been a route to reverse opioid tolerance, implicating 
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morphine or its accumulating metabolite morphine-3-glucuronide in the 
phenomenon (Andersen et al., 2003; Sjøgren et al., 1994; Smith, 2000).  
Pharmacokinetic factors, such as decreased absorption of oral preparations, 
accelerated drug elimination in the liver and kidney, or changes in the BBB drug 
transport function may lead to decreased opioid access to the CNS (see 2.3.5). It is 
also important to distinguish the marked differences between the actions of M3G 
and M6G, the primary metabolites of morphine in humans. Upon morphine 
administration, both metabolites are observable in the brain, even though they 
have limited permeability through the BBB (Bickel et al., 1996). Systemically 
administered M6G is approximately twice as potent as morphine in humans 
(Osborne et al., 1990) and also in animal models (Paul et al., 1989). During 
prolonged oral administration in humans, the plasma concentration of M6G 
generally exceeds that of morphine. In rats, however, M6G is not formed at 
detectable concentrations (Coughtrie et al., 1989). M3G, the other primary 
metabolite of morphine, has the opposite actions. It has very little affinity for the 
opioid receptor, but may contribute to the harmful excitatory effects of morphine 
and OIH (Andersen et al., 2003; Sjøgren et al., 1994; Smith, 2000).  
On an individual level, there are marked differences in the variation of the 
response to a given opioid. The genetics involved in opioid pharmacodynamics or 
pharmacokinetics may play a role in the response to opioid drugs, but their 
influence on this variation is complex. Personalized medicine is a rising field of 
medicine that aims at the customization of medical treatment to personally suit 
the needs of an individual patient. The majority of genetic studies have so far 
focused on single genes or single nucleotide polymorphisms, and research into the 
involvement of gene–gene interactions in the opioid response is only just starting; 
for a review, see Branford et al. (2012). Environmental factors that cause changes 
in chromosomes without altering the deoxyribonucleic acid (DNA) sequence by 
altering gene transcription are called epigenetics. Chronic opioid exposure may 
stimulate DNA methylation at the mu-opioid receptor coding OPRM1 gene. This 
finding did not induce increased opioid dosing requirements, but was associated 
with increased chronic pain. The mechanism is still unresolved, but may provide a 
new interesting approach to research on OIH (Doehring et al., 2013). 
In conclusion, the need for opioid dose elevation during chronic 
administration in a clinical setting may be a sum of the pharmacologic opioid 
tolerance, non-associative tolerance, OIH, alterations in pharmacokinetics, and 
disease progression. Genetic factors also have to be considered. 
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2.3.2 Role of the glutamatergic system in opioid tolerance and opioid-induced 
hyperalgesia 
Adaptation to opioid use can also result from the upregulation of glutamate and 
other pathways in the brain, which can exert an opioid-opposing effect and 
thereby reduce the effects of opioid drugs by altering downstream pathways, 
regardless of mu-opioid receptor activation. Extensive research has centered on the 
excitatory amino acid system, in particular the NMDA receptors. These are 
ionotropic glutamate receptors that are crucial for excitatory synaptic transmission. 
They are involved in numerous cognitive processes such as learning and synaptic 
plasticity. In the resting state, the receptor is blocked by Mg2+. Activated NMDA 
receptors are permeable to Ca2+, Na+, and K+ (Frohlich and Van Horn, 2014). 
Acute pain is mainly signaled by the release of glutamate from the central 
terminals of primary afferents, which after binding to alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors causes transient 
excitatory postsynaptic currents (EPSCs) in second-order dorsal horn neurons. 
The sum of these EPSCs may lead to an action potential and transmission to 
high-order neurons. During the constant barrage of action potentials from the 
periphery, the increased neurotransmitter release and postsynaptic depolarization 
will be long enough to activate NMDA receptors (Frohlich and Van Horn, 2014). 
Functional NMDA receptors (Fig. 5) are heteromeric complexes consisting 
of a NR1 subunit and modulatory subunits of the NR2 (NR2A–D) family 
(Frohlich and Van Horn, 2014). NMDA receptors are involved in synaptic long-
term modulation (long-term potentiation) and glutamate neurotoxicity when 
overactivated. Systemic administration of the NMDA receptor antagonists MK-
801 or ketamine has been shown to reverse opioid-induced mechanical or thermal 
hyperalgesia and opioid tolerance after acute or chronic opioid administration in 
numerous studies (Li et al., 2001b; Manning et al., 1996; Mao et al., 2002; 
Trujillo and Akil, 1991; 1994); for a review, see Angst and Clark (2006). In many 
of the studies, a role for the intracellular effector PKC has been suggested to lie 
behind the induction of OIH, as PKC may upregulate NMDA receptors, and the 
development of OIH was not observed in PKC-gamma knockout mice (Célérier 
et al., 2004; Zeitz et al., 2001). Interestingly, increased nociception and 
hyperalgesia after opioid infusion was also observed in opioid receptor triple 
knockout mice lacking all three genes encoding opioid receptors (Juni et al., 2007), 
demonstrating a opioid receptor-independent route of hyperalgesia development. 
Furthermore, the development of hyperalgesia could be reversed by the NMDA 
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antagonist MK-801 in control (wild-type) mice, but not in opioid receptor 
knockout mice, indicating that other mechanisms also contribute to the 
development of hyperalgesia (see 2.3.3). In another triple knockout study using 
acute fentanyl injections, the development of hyperalgesia could be reversed by an 
MK-801 co-injection (Waxman 2009).  
 
 
 
 
 
Figure 5. Schematic 
representation of 
the N-methyl-D-
aspartate receptor 
complex.  
PCP, phencyclidine. 
Adapted from 
Frohlich and Van 
Horn (2014). 
 
 
 
Glial cells may also influence the clearance of neurotransmitters, especially 
glutamate, from the synaptic cleft. Chronic morphine induced downregulation 
of the astrocyte glutamate transporters glial glutamate transporter 1 (GLT-1) 
and glutamate aspartate transporter (GLAST) (Mao et al., 2002; Sung et al., 
2003), leading to increased glutamate and synaptic transmission, morphine 
tolerance, and thermal hyperalgesia. Glia also incorporate NMDA receptors that 
have a different subunit configuration compared to neurons, making them less 
permeable to Ca2+. The function and significance of glial NMDA receptors has 
not yet been established; for a review, see Dzamba et al. (2013). 
Finally, excess glutamate may also play a role in functional changes and 
the expression of drug transporters at the BBB. Glutamate was shown to 
upregulate P-gp expression in microvessel endothelial cells of the rat brain (Zhu 
and Liu, 2004), a phenomenon that was attenuated by the NMDA receptor 
antagonist MK-801, implying an NMDA receptor-mediated mechanism behind 
the finding. A simplified representation of the glumatergic system in opioid 
tolerance is presented in Figure 6. 
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Figure 6. A simplified representation of the glutamatergic system in opioid tolerance at the 
spinal cord level.  
1. Morphine administration in acute pain.  
2. Chronic pain, opioid tolerance and opioid-induced hyperalgesia.  
EAAT, excitatory amino acid transporter; Glu, glutamate; Mo, morphine; MOR, mu-opioid 
receptor; NMDAR, N-methyl-D-aspartate receptor.  
é, increased concentration or activity; ê, decreased concentration or activity. 
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2.3.3 Glial cells and opioid antinociception  
Recent years have seen the introduction the neuroimmune interface as a new 
concept of modulating CNS neurotransmission. Neuronal excitability can be 
notably enhanced by the classical neuronal transmitters, but also by immune 
mediators released from glial cells in the CNS as well as infiltrating cells such as 
T cells and macrophages. In several painful conditions discussed below, glial 
cells function in enhancing pain sensitivity via neuroglial interactions. Opioid 
treatment may also cause glial activation, which may attenuate the analgesic 
potency of opioids. 
Glial cells of the CNS consist of three distinct types of cells: astrocytes, 
microglia, and oligodendrocytes. In the peripheral nervous system (PNS), glial 
cells are found as satellite glial cells (SGCs) in the dorsal root ganglia (DRGs) 
and trigeminal ganglia (TGs), and as Schwann cells enclosing the peripheral 
nerves (Gao and Ji, 2010; Hutchinson et al., 2011). 
The most numerous glia in the CNS are called astrocytes. They have an 
essential role in the regulation of the chemical content of the extracellular space. 
Astrocytes form a complex network, an envelope, over the synaptic junctions in 
the brain to restrict the spread of neurotransmitters. They also communicate 
intercellularly via Ca2+ signaling. Astrocytes are typically immunostained with 
the detection of glial fibrillary acidic protein (GFAP), although this only stains 
the major branches of the cells. Astrocytes are a part of the “tripartite synapse” 
theory, in which glial cells have a crucial role as active modulators of synaptic 
transmission. Glia may react to neuronal activity and either enhance or suppress 
neuronal activity and the synaptic strength with chemical transmitters (Gao and 
Ji, 2010; Hutchinson et al., 2011; Ji et al., 2013).  
Oligodendroglial cells provide layers of membrane that insulate the 
neuronal axons. One oligodendroglial cell can provide myelin for several axons 
(Hutchinson et al., 2011). 
Microglial cells are responsible for the primary immune response in the 
brain. These cells originate from bone marrow-derived monocytes that migrate 
to the CNS during the prenatal period. Their distribution in the CNS is 
heterogeneous, and they account for 5–12% of its cells. Under normal conditions, 
microglia are considered inactivated, but they continuously sense their 
environment with their ramified processes (Nimmerjahn et al., 2005). Under any 
kind of brain damage or injury, microglia are activated and undergo 
morphological and functional changes. The most selective markers for microglia 
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are intracellular proteins CD11b (cluster of differentiation molecule 11b) and 
ionized calcium-binding adapter molecule 1 (Iba1, also known as allograft 
inflammatory factor 1, AIF1) (Fig. 7). In peripheral nerve injury, the spinal 
microglia become activated and their morphology changes from a ramified to an 
ameboid shape (Suter et al., 2007). 
 
 
Glia exert different types of functional changes upon neuronal injury or 
continuous painful stimulation. Many studies have defined glial activation as 
upregulation of glia-selective markers. This is often associated with 
morphological changes such as cell hypertrophy. Upregulation of these markers 
has been demonstrated in numerous experimental pain states, for example nerve 
injury, spinal cord injury, paw incision, joint arthritis, cancer, chemotherapy, and 
diabetes models; for reviews, see Grace et al. (2014) and Ji et al. (2013). Chronic 
morphine exposure has also been shown to result in considerable upregulation of 
the microglial markers Iba1 and CD11b (Daulhac et al., 2006; Wen et al., 2009; 
Zhou et al., 2010; Zhu et al., 2014), as well as the astrocyte marker GFAP 
(Song and Zhao, 2001) in the spinal cord. 
Another indicator of glial cell activation is the upregulation of intracellular 
signaling cascade proteins such as the MAPK family. These pathways have an 
important role in the intracellular signaling of glia. The enhanced function of 
MAPKs by phosphorylation is essential for the development of chronic pain (Ji 
et al., 2009), and phosphorylation of p38, a MAPK family member, has been 
observed during chronic opioid treatment (Cui et al., 2006). Thirdly, many 
receptors and transporters having a role in glial intracellular signaling are 
regulated in painful states. At present, there is evidence for the upregulation of 
Figure 7. Iba1 
immunohistochemical 
staining of microglial cells 
in the brain cortex of the 
rat. 200 ×	 magnification. 
Iba1, ionized calcium-
binding adapter 
molecule 1. (Lilius et al., 
unpublished) 
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purinergic P2X4 and P2X7 ion channel receptors in spinal microglia (Horvath 
and DeLeo, 2009; Zhou et al., 2010). 
Toll-like receptors (TLRs) are important regulators of innate immunity 
(Nicotra et al., 2012) by sensing various xenobiotic substances, for example 
bacterial parts (lipopolysaccharide, LPS), as well as drugs such as opioids. 
Activation of the TLR4-MD2 (lymphocyte antigen 96) receptor complex has 
been shown to cause activation of both microglia and astrocytes. Morphine was 
suggested to induce glial responses via the TLR4-MD2 complex (Wang et al., 
2012b; Watkins et al., 2009), and the blockade of TLR4-MD2 inhibited the 
development of opioid tolerance, withdrawal and hyperalgesia. Interestingly, 
glial activation via TLR4 was also observed when mu-opioid receptor inactive 
(+) opioid isomers were administered (Hutchinson et al., 2010a). In two studies, 
however, morphine-induced hyperalgesia was not altered in mice with Tlr4 gene 
knockout (Ferrini et al., 2013), and morphine tolerance developed similarly as in 
wild-type animals (Fukagawa et al., 2012). 
The effects of opioids on glial cell activation have been reported in 
multiple studies, with Song and Zhao being the first to report the phenomenon 
(Song and Zhao, 2001). Particularly in the spinal cord, glial activation after 
chronic intrathecal and/or systemic morphine administration has been 
demonstrated by multiple methods, such as upregulation of the astroglial marker 
GFAP (Cui et al., 2006; 2008; Huang et al., 2012; Raghavendra et al., 2002; 
2004; Song and Zhao, 2001; Zhou et al., 2010) and the microglia-selective 
markers Cd11b and Iba1 (Cui et al., 2006; Ferrini et al., 2013; Horvath et al., 
2010; Liu et al., 2006; Raghavendra et al., 2002; Shen et al., 2011; Tai et al., 
2009; 2006; Zhou et al., 2010). After morphine, a smaller number of studies 
have shown GFAP and/or Iba1 upregulation in multiple brain areas, such as the 
ventral tegmental area, nucleus accumbens, and frontal cortex (Garrido et al., 
2005), the posterior cingulate cortex and hippocampus (Song and Zhao, 2001), 
PAG (Eidson and Murphy, 2013; Hutchinson et al., 2009), and midbrain 
(Harada et al., 2013). In several studies, glial activation has been indirectly 
observed by upregulation of glial cell membrane receptors such as P2X4 
(Horvath et al., 2010), P2X7 (Zhou et al., 2010), and upregulation of the 
intracellular p38 protein (Cui et al., 2006; 2008; Liu et al., 2006).  
Glial cells affect neural pain processing via soluble mediators that may be 
released for months after an injury or insult as a result of pathological activation 
(Milligan et al., 2006). Compared with classical neurotransmitters, glia-secreted 
immune modulators may modulate spinal cord neurotransmission at much lower 
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concentrations (Ji et al., 2013). Many immune modulators such as tumor 
necrosis factor (TNF), interleukin (IL)-1 beta, and interferon gamma (IFN-
gamma) are capable of directly affecting excitatory transmission by increasing 
glutamate release from primary afferent neurons (Gao et al., 2009; Kawasaki et 
al., 2008; Nishio et al., 2013; Yan and Weng, 2013; Zhang et al., 2010). 
Another mechanism for increased synaptic transmission may be increased 
surface AMPA receptor expression or phosphorylation of the NMDA receptor 
(Meng et al., 2013; Stellwagen et al., 2005; Viviani et al., 2003; Zhang et al., 
2008). Increased release of proinflammatory cytokines by glia after morphine has 
been documented (Shen et al., 2011; Tai et al., 2009; 2006). However, the 
activation of spinal cord glia has been much more extensively studied compared 
with different supraspinal areas. Furthermore, all of these studies have been 
conducted with morphine as the study opioid. 
The efficacy of several glia-affecting drugs has been investigated in various 
models of opioid antinociception. Minocycline, a broad-spectrum tetracycline 
antibiotic and glial inhibitor, enhanced opioid-induced acute antinociception 
and attenuated morphine tolerance (Cui et al., 2008; Hutchinson et al., 2008a; 
2008b). Interestingly, it also reduced opioid-induced respiratory depression 
(Hutchinson et al., 2008b). Ibudilast (AV411), a nonspecific phosphodiesterase 
(PDE) inhibitor, enhanced opioid antinociception both acutely and in models of 
opioid tolerance (Hutchinson et al., 2009; Ledeboer et al., 2006), as well as 
reducing spontaneous and precipitated opioid withdrawal periods (Hutchinson 
et al., 2009). The xanthine derivatives propentofylline and pentoxifylline, both 
inhibitors of PDE and antagonists of adenosine receptors, have shown promise 
in opioid antinociception in neuropathic pain and opioid tolerance (Mika, 2008; 
Mika et al., 2007; Raghavendra et al., 2004). For a more extensive review, see 
Watkins et al. (2009). 
2.3.4 Opioids and the alpha-2-adrenergic receptors 
Catecholamine receptors are G protein-coupled receptors divided into two 
categories, alpha- and beta-adrenoceptors. Alpha-adrenoceptors are further 
divided to subtypes 1A, 1B, 1D, 2A, 2B, and 2C. Alpha-2-adrenoceptors 
decrease intracellular adenylyl cyclase activity through Gi, or they may also 
modify the activity of ion channels (Na+/H+ antiport, Ca2+ or K+ channels). 
Adrenoceptors located in catecholaminergic neurons are called autoreceptors, 
and those located in non-adrenergic neurons are called heteroceptors. The 
autoreceptors may be located at presynaptic axon terminals, where they inhibit 
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the release of the neurotransmitter, whereas in the somatodendritic area they 
inhibit impulse discharge (Westfall and Westfall, 2011). 
In the periphery, the main source of catecholamines is the postganglionic 
sympathetic nerve fibers, mainly releasing norepinephrine, and the adrenal 
medulla, mainly releasing epinephrine. In the DRG, the subtype alpha-2C is the 
most common, followed by alpha-2A receptors, whereas alpha-2B is rare (Shi et 
al., 2000). Whether the peripheral alpha-2-adrenoceptor system promotes pain 
facilitation or suppression strongly depends on the pain model and time course. In 
physiological conditions, peripheral norepinephrine has only minor effects on pain, 
but in conditions of inflammation and neuropathy it may aggravate pain (Davis et 
al., 1991; Drummond, 1995; Torebjörk et al., 1995). Peripheral nerve sprouting 
and the formation of new adrenoceptors may follow inflammation and injury, 
which may have a role in maintaining hyperalgesia (Baron, 2000). It is not exactly 
known which subtypes of adrenoceptors in the periphery contribute to the 
aggravation and which to the inhibition of pain.  
In the CNS, the spinal cord and its dorsal horn is critical for the ascending 
nociceptive pathways. It receives noradrenergic innervation from the modulatory 
descending noradrenergic pathways.  The source for the spinal norepinephrine is 
located in axons descending from noradrenergic nuclei in the pons and brainstem 
(Jones, 1991; Kwiat and Basbaum, 1992). These nuclei, in turn, receive important 
projections from PAG (Bajic and Proudfit, 1999). The descending noradrenergic 
fibers have sparse axon-axon contacts with central terminals of the primary 
afferent fibers (Hagihira et al., 1990); however, contacts with the descending 
noradrenergic axons and the spinal dorsal horn neurons are abundant (Doyle and 
Maxwell, 1991). It is also possible that the noradrenergic influence on spinal 
dorsal horn neurons is mainly non-synaptic, i.e. the transmitter acts by diffusion 
from the release site to the site of action (Rajaofetra et al., 1992; Zoli and Agnati, 
1996). The alpha-2A-adrenoceptor is localized in the whole dorsal horn (Shi et 
al., 1999), especially on the primary afferent nociceptor nerve terminals (Stone et 
al., 1998). The alpha-2C receptors are probably located on the axon terminals of 
spinal excitatory interneurons (Olave and Maxwell, 2003), whereas the expression 
of the 2B-type receptor is only minute in postnatal animals. 
In supraspinal areas, alpha-2-adrenoceptors are widely distributed. The 
subtype 2A is common throughout the brain, whereas subtypes 2B and 2C have 
specific localizations (2B in the thalamus and 2C prominently in the striatum) 
(Scheinin et al., 1994). 
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The most important mechanism for alpha-2-adrenoceptor-mediated pain 
regulation occurs in the spinal dorsal horn. Pain signaling is attenuated by 
reducing the release of excitatory amino acids from the primary afferent nerve 
fibers (Kawasaki et al., 2003; Pan et al., 2002), but also by inducing 
hyperpolarization by activating K+ currents in spinal pain-relay neurons (Sonohata 
et al., 2004). It is likely that the 2A subtype of the alpha-adrenoceptors mediates 
both of these effects, as alpha-2-agonists failed to induce antinociception after the 
knockout of alpha-2A-adrenoceptors (Lakhlani et al., 1997; Stone et al., 1997). 
The activity of the spinal noradrenergic inhibitory pathways seems to be rather 
inactive in animals without sustained pain, because the knockout of any of the 
receptor subtypes had no effect on stimulus-evoked pain. In chronic pain, however, 
the alpha-2A receptor subtype in particular seems to be involved in noradrenergic 
feedback inhibition (Mansikka et al., 2004). At supraspinal sites, despite the fact 
that every major structure responsible for processing pain signaling has 
noradrenergic receptors, their regulatory role is not yet well established. The 
effects of alpha-2-antagonists have been contradictory, depending on the pain 
model and supraspinal area that has been under research. 
The interplay between the alpha-2-adrenergic system and the opioidergic 
system has been under extensive research. Spinal administration of morphine or 
other opioids produces marked analgesia, which is mediated by opioid receptors 
located both pre- and postsynaptically in the terminals of the nociceptive primary 
afferent neurons and the dorsal horn neurons, respectively. During prolonged 
administration of either opioids or alpha-2-adrenoceptor agonists, pharmacologic 
tolerance to the drug action is observed (Milne et al., 1985; Quartilho et al., 2004; 
Reddy and Yaksh, 1980; Takano and Yaksh, 1992). Numerous in vivo studies 
investigating the functional interaction between opioid receptors and alpha-2-
adrenoceptors have shown that animals tolerant to intrathecal morphine also show 
tolerance to alpha-2-agonist antinociception (Milne et al., 1985; Stevens et al., 
1988), and opioid receptor antagonists can antagonize the antinociceptive action 
of spinal norepinephrine or other alpha-2-adrenoceptor agonists (Roerig et al., 
1992; Sullivan et al., 1992). On the contrary, adrenoceptor antagonists, including 
the alpha-2-adrenoceptor antagonist yohimbine, have been shown to antagonize 
opioid-induced antinociception (Bentley et al., 1983; Browning et al., 1982). 
Furthermore, Aley and Levine (1997) showed that antagonists for mu-opioid 
receptors and alpha-2-adrenoceptors antagonized the effect of agonists activating 
the other receptor. 
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However, some recent findings concerning the interplay between the alpha-2-
receptor and mu-opioid receptor render the interpretation of the supposed drug 
effects more complex. Milne et al. (2008) reported that ultralow doses (an ultra-
low dose is defined as a dose several log units lower than the dose required to 
produce functional antagonism at the respective receptor) of four structurally 
different intrathecally administered alpha-2-adrenoceptor antagonists 
(atipamezole, yohimbine, mirtazapine, and idazoxan) increased acute spinal 
morphine antinociception, attenuated the induction of acute and chronic tolerance, 
and also reversed the already established morphine tolerance in rats. The same 
group has also demonstrated an augmentation in clonidine and norepinephrine 
antinociception after coadministration of atipamezole (Milne et al., 2011). 
Moreover, ultralow doses of systemic or intrathecal naltrexone, an opioid receptor 
antagonist, administered systemically or intrathecally had a paradoxical additive 
effect on the antinociceptive effect of morphine in heat nociception and also 
blocked the development of tolerance (Powell et al., 2002). This has additionally 
been shown in a model of neuropathic pain in rats (Largent-Milnes et al., 2008). 
Similar effects were noted with ultralow doses of selective mu-, delta- and kappa-
opioid receptor antagonists (Abul-Husn et al., 2007; McNaull et al., 2007). 
G protein-coupled receptors normally act as monomeric cell surface 
receptors, but there is increasing evidence that G protein-coupled receptors may 
also form homo- and heterodimeric complexes. Interestingly, mu-opioid and 
alpha-2A receptors may form heterodimers at the plasma membrane of cultured 
cells as well as in primary spinal cord neurons (Jordan et al., 2003). The activation 
of either monomeric mu-opioid or alpha-2A-adrenoceptors normally mediates a 
parallel signaling effect, leading to antinociception at the spinal level. However, 
the simultaneous activation of both the mu-opioid- and alpha-2A-adrenoceptors 
in heterodimer complexes changes the cellular response, which is not an additive 
effect (Jordan et al., 2003). Activation of either mu-opioid or alpha-2A receptors 
leads to increased signaling, whereas activation of both receptors decreases the 
response. Moreover, an in vitro study (Vilardaga et al., 2008) has shown that in 
the heterodimer complexes, the mu-opioid and alpha-2A receptors communicate 
with each other through a cross-conformational switch that allows the direct 
inhibition of one receptor by the other. Binding of morphine to the mu-opioid 
receptor triggers a conformational change in the norepinephrine-occupied alpha-
2A-adrenoceptor that inhibits its signaling. Norepinephrine has been shown to 
inhibit morphine-mediated G protein activation, suggesting that a conformational 
change may also take place in the opposite direction (Jordan et al., 2003). 
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Endogenous norepinephrine could inhibit the effect of morphine in heterodimers 
through these mechanisms. Supporting the alpha-2A and opioid receptor-
interplay related nociceptive changes, the antinociceptive effect of morphine and 
especially tramadol was increased in alpha-2A-adrenoceptor knockout mice 
(Ozdoğan et al., 2006). 
Another theory for the mechanism behind the paradoxical augmentation of 
opioid agonists by ultralow doses of opioid antagonists has been postulated. Wang 
et al. (2008) showed that cotreatment with 10 ng/kg naloxone prevented the 
chronic morphine-induced Gi/Go-to-Gs switch in mu-opioid receptor G protein 
coupling. While opioid receptors in a normal state preferentially bind to Gi or Go 
proteins to inhibit adenylyl cyclase (Laugwitz et al., 1993), chronic morphine 
treatment may induce a switch to Gs coupling (Chakrabarti et al., 2005; Wang et 
al., 2008), leading to cAMP accumulation. A subgroup of mu-opioid receptors 
preferentially binding to Gs proteins has also been proposed, but the naloxone dose 
of 10 ng/kg has been estimated to occupy only 1% of mu-opioid receptors, which 
is not sufficient for antagonizing the supposed Gs-binding subpopulation of mu 
receptors (Lewanowitsch and Irvine, 2003). Moreover, an ultra-low dose of 
naloxone reduced Gs coupling and restored levels of coupling to native Gi or Go 
proteins (Wang et al., 2005). In further studies by the same group, naloxone was 
found to bind with high affinity to filamin A, a 300-kDa protein co-
immunoprecipitating with mu-opioid receptors (Wang et al., 2008). Filamin A is 
known as a large cytoplasmic protein responsible for regulating cell signaling by 
interacting with various receptors and signaling molecules, including the mu-
opioid receptor (Onoprishvili et al., 2003). The ultimate hypothesis is that 
naloxone binding to filamin A prevents morphine tolerance and hyperalgesia by 
inhibiting mu receptor coupling to excitatory Gs proteins. Interestingly, filamin A 
may also inhibit the signaling cascades of the TLR4-MD2 receptor complex 
(Wang et al., 2012a). Whether ultralow antagonists of alpha-2-adrenergic 
receptors also have affinity for filamin A or other closely mu-opioid receptor 
related proteins remains to be shown. Table 2 presents the current evidence for the 
paradoxical enhancement of opioid antinociception by either opioid receptor or 
alpha-2-adrenoceptor antagonists.  
In clinical studies, ultralow-dose naloxone combined with morphine in 
patient controlled analgesia (PCA) led to decreased nausea and pruritus, but did 
not affect analgesia or opioid requirements (Cepeda et al., 2004). When the 
administered naloxone concentration was ten times greater (6 µg/ml with an initial 
setting of 0.5 ml bolus per demand), the combination led to poorer pain relief than 
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morphine alone (Cepeda et al., 2002). Chindalore et al. (2005) reported that 
Oxytrex, a preparation that combines oxycodone with ultralow-dose naltrexone, 
enhanced and prolonged analgesia compared with oxycodone alone in patients 
suffering from osteoarthritis. Thus, it seems that in patients the choice of the 
ultralow dose may far more difficult than in laboratory animals. 
Interestingly, the alpha-2-adrenoceptor is also expressed in glial cells (Hösli 
et al., 1982), but its role in glial reactivity has not been thoroughly researched and 
has produced some contradictory results. For example, Yan et al. (2011) 
demonstrated that dexmedetomidine, an alpha-2-adrenoceptor agonist, stimulated 
astrocyte activation and glial cell line-derived neurotrophic factor (GDNF) 
production in vitro. In vivo, the alpha-2-adrenoceptor antagonist yohimbine (at a 
dose large enough to antagonize morphine antinociception) was shown to reduce 
GFAP upregulation induced by chronic morphine administration (Alonso et al., 
2007; Garrido et al., 2005). 
  
(Table 2 continued) 
Drug studied Pain model Outcome Route, subject Reference 
POSITIVE FINDINGS  
Nonselective opioid 
receptor antagonist 
naloxone 
Intrathecal morphine tolerance: thermal 
nociception 
 
Inhibition of development of intrathecal morphine tolerance, 
inhibition of Gs coupling and Gβγ signaling to adenylyl cyclase, 
increasing Gi/o coupling 
i.t., rat Wang et al., 
2005 
Inhibition of 1) development of intrathecal morphine tolerance, 2) 
glutamate transporter downregulation, 3) NMDAR NR1 subunit 
phosphorylation 4) PKC-gamma expression, 5) glial cell activation, 
6) excitatory amino acid release 
i.t. infusion, rat Lin et al., 
2010 
Remifentanil infusion-induced hyperalgesia 
during sevoflurane anesthesia  
Reduction of needed minimum alveolar concentration (MAC) of 
sevoflurane 
i.v. infusion, rat Aguado et 
al., 2013 
Intrathecal PTX-induced thermal 
hyperalgesia 
Preservation of morphine antinociception, suppression of PTX-
induced excitatory amino acid release, inhibition of microglial 
activation, suppression of cytokine release 
i.t., rat Tsai et al., 
2008 
Nonselective opioid 
receptor antagonist 
naltrexone 
 
 
 
  
Acute thermal and mechanical nociception  Prolongation of intrathecal and augmentation of systemic 
morphine antinociception 
i.t. and s.c., rat Powell et 
al., 2002 
Intrathecal or systemic morphine tolerance: 
acute thermal and mechanical nociception  
Inhibition of development of intrathecal morphine tolerance; 
restoration of morphine antinociceptive potency in developed 
tolerance 
Intrathecal morphine tolerance: acute 
thermal nociception  
 
Inhibition of development of intrathecal morphine tolerance; 
restoration of morphine antinociceptive potency in developed 
tolerance 
i.t., female and 
male SD and LE 
rats 
Terner et 
al., 2006 
Inhibition of development of i.t. morphine tolerance, attenuation 
of microglial and astrocyte activation 
i.t., rat Mattioli et 
al., 2010 
Intrathecal or oral oxycodone 
antinociception in spinal nerve ligation-
induced hyperalgesia 
Reduction of allodynia and hyperalgesia after SNL and oxycodone 
treatment, attenuation of Gs coupling 
i.t., rat Largent-
Milnes et 
al., 2008 
  
Table 2. Current evidence for the paradoxical enhancement of opioid- or alpha-2-adrenoceptor agonist antinociception by 
coadministration of ultralow doses (a dose several log units lower than the dose required to produce functional antagonism at the 
respective receptor) of either opioid receptor or alpha-2-adrenoceptor antagonists. CTOP, D-Phe- Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; 
CTAP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2; PTX, pertussis toxin; SD, Sprague-Dawley, LE, Long Evans. 
 
Drug studied Pain model Outcome Route, subject Reference 
POSITIVE FINDINGS  
Alpha-2-adrenoceptor antagonists 
atipamezole, yohimbine, 
mirtazapine, and idazoxan  
Acute thermal and mechanical nociception Prolongation of intrathecal morphine antinociception i.t., rat Milne et al., 
2008 Intrathecal morphine tolerance: acute 
thermal and mechanical nociception 
Inhibition of development of intrathecal morphine 
tolerance; restoration of morphine antinociceptive 
potency in developed tolerance 
Alpha-2-adrenoceptor antagonist 
atipamezole 
Acute thermal and mechanical 
antinociception 
Prolongation of intrathecal clonidine (tail-flick and hot 
plate) and norepinephrine (tail-flick only) 
antinociception 
i.t., rat Milne et al., 
2011 
Intrathecal norepinephrine antinociceptive 
tolerance: acute thermal and mechanical 
antinociception 
Inhibition of development of intrathecal norepinephrine 
antinociceptive tolerance 
Alpha-2-adrenoceptor antagonist 
efaroxan, (+) and (±) isomers but 
not the (-) isomer 
Intrathecal morphine tolerance: acute 
thermal and mechanical nociception 
Inhibition of development of intrathecal morphine 
tolerance 
i.t., rat Milne et al., 
2013 
Alpha-2-adrenoceptor antagonists 
efaroxan, atipamezole, and 
yohimbine 
Low-dose intrathecal morphine thermal 
hyperalgesia 
Inhibition of acute morphine thermal hyperalgesia 
 
 
 
  
 (Table 2 continued) 
Drug studied Pain model Outcome Route, subject Reference 
POSITIVE FINDINGS  
Mu-opioid receptor antagonists 
CTOP and CTAP and delta-opioid 
receptor antagonist naltrindole 
Acute thermal and mechanical 
nociception 
Prolongation of intrathecal morphine antinociception i.t., rat Abul-Husn 
et al., 2007 
Intrathecal morphine tolerance: 
acute thermal and mechanical 
nociception 
Inhibition of development of intrathecal morphine tolerance; 
restoration of morphine antinociceptive potency in developed 
tolerance 
Mu-opioid receptor antagonist 
CTAP, delta-opioid receptor 
antagonist naltrindole, kappa-
opioid receptor antagonist nor-
binaltorphimine and nonselective 
opioid receptor antagonist 
naltrexone 
Acute thermal and mechanical 
nociception 
Prolongation of intrathecal morphine antinociception i.t., rat McNaull et 
al., 2007 
Intrathecal morphine tolerance: 
acute thermal and mechanical 
nociception 
Inhibition of development of intrathecal morphine tolerance 
Low-dose systemic and intrathecal 
morphine thermal hyperalgesia 
Inhibition of acute thermal hyperalgesia i.t. and s.c., rat 
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2.3.5 Access of morphine and other opioids to the central nervous system 
Clinically, one interesting developing line of research is the study of opioid 
pharmacokinetics and drug–drug interactions for the improvement of opioid 
efficacy. The CYP450 family enzymes only have an effect on the metabolism of 
opioids, whereas several drug transporter proteins may affect the absorption, 
distribution, and excretion of opioid drugs (Mercer and Coop, 2011). Recent 
preclinical evidence suggests that the BBB efflux transporters may contribute to 
opioid efficacy and the development of tolerance. P-gp, a member of the ATP-
binding cassette (ABC) superfamily, is one of the best characterized efflux 
transporters to date. It has functions in the extrusion of xenobiotics and uptake 
of nutrients (Hennessy and Spiers, 2007). In the brain, the expression of P-gp is 
high in the frontal cortex, choroid plexus, and PAG, with lower levels in the 
cerebellum and hippocampus (King et al., 2001). 
A role of P-gp in the transport of opioids was first observed by Callaghan 
and Riordan in an in vitro system (Callaghan and Riordan, 1993). Since then, 
multiple in vivo and in vitro studies have been conducted with different 
experimental approaches to confirm this finding. In Caco-2 and L-MDR1 cells, 
morphine was acknowledged as a weak P-gp substrate with a efflux:influx ratio 
of 1.5 (Crowe, 2002; Wandel et al., 2002), a ratio that was supported by in situ 
studies (P-gp effect of 1.24) (Dagenais et al., 2004). In P-gp knockout mice, 
morphine antinociception was increased and prolonged (Thompson et al., 2000). 
Human evidence is sparse and it only consists of acute studies in healthy 
volunteer subjects. In the presence of the P-gp inhibitor quinidine, enhanced 
CNS effects were not experienced after an i.v. morphine dose (Skarke et al., 
2003), whereas increased plasma concentrations but no influence on morphine 
pharmacodynamics after morphine p.o. administration were observed in another 
study (Kharasch et al., 2003). Finally, pharmacokinetic modeling for morphine 
has been employed, resulting in three major factors limiting the access of 
morphine to the brain: limited passive diffusion, active efflux, and low-capacity 
active uptake (Groenendaal et al., 2007). Interestingly, a variety of the P-gp gene 
ABCB1 polymorphisms have been discovered, and variability in pain relief in 
cancer patients was noted with the 3435C>T variant (Sai et al., 2006). 
Much less information exists on the interaction of other opioids and P-gp. 
For the commonly used oxycodone, there are conflicting results (Boström and 
Simonsson, 2005; Hassan et al., 2007). Interestingly, a correlation for P-gp and 
the CYP3A substrate co-specificity exists (Schuetz et al., 1996; Wacher et al., 
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1995), and oxycodone is an example of this phenomenon (Hassan et al., 2007; 
Lalovic et al., 2004). Loperamide, a peripherally restricted opioid often used as 
an anti-diarrheal drug, has been identified as a good P-gp substrate with an 
efflux:influx ratio of 10 (Wandel et al., 2002). In P-gp knockout mice, its 
concentration was increased 13-fold in the brain and doubled in plasma 
(Schinkel et al., 1995), suggesting that P-gp is a key factor in constraining 
loperamide to the periphery. 
A number of studies have implicated the upregulation of the BBB P-gp in 
morphine tolerance (Aquilante et al., 1999; Hassan et al., 2009; King et al., 
2001; Mercer and Coop, 2011; Yousif et al., 2012). Aquilante et al. (1999) 
reported that the whole brain P-gp content was doubled in morphine-tolerant 
rats. Oxycodone was also shown to induce P-gp up to 4-fold in the liver and 1.3-
fold in brain tissues (Hassan et al., 2007), but in a transcriptome study, the P-gp 
(Abcb1) mRNA levels were not increased (Hassan et al., 2009). Furthermore, 
King et al. (2001) reported that P-gp antisense or mismatch treatment 
eliminated morphine tolerance. Interestingly, in all these studies, measurements 
were conducted at the withdrawal phase, pointed out by Yousif et al. (Yousif et 
al., 2012). In their study, the expression of P-gp and breast cancer resistance 
protein (Bcrp) after chronic morphine administration was not directly 
upregulated after the last morphine dose, but only after 9 hours of the last dose. 
They hypothesized that P-gp upregulation is not induced by chronic morphine 
administration itself, but by the following withdrawal period. Furthermore, the 
expression of P-gp and Bcrp was clearly downregulated by the administration of 
MK-801 (NMDA receptor antagonist) or meloxicam (cyclooxygenase-2 
inhibitor) after the last morphine dose.  
Only a few studies have reported other transporters than P-gp for 
morphine. Bcrp was not found to transport morphine, even though chronic 
morphine induced it (Tournier et al., 2010; Yousif et al., 2012). Like P-gp, 
multidrug resistance protein (Mrp) is a member of the ABC superfamily of 
transport proteins. In the brain, Mrp is expressed in the cerebellum, PAG, and 
hippocampus, and at lower levels in the frontal cortex and choroid plexus (Su 
and Pasternak, 2013). In the same study, morphine displayed increased 
antinociception after Mrp antisense administration. Dose–response studies have 
revealed a twofold-enhanced potency of morphine after Mrp downregulation. 
Furthermore, in the Mrp antisense group, morphine antinociception in repeated 
intracerebroventricular (i.c.v.) administration developed significantly more slowly, 
indicating slower transport from the cerebrospinal fluid to the blood. Rao et al. 
Review of the literature 
 
45 
(1999) utilized a choroid plexus (blood–cerebrospinal fluid barrier) model to 
suggest that Mrp and P-gp are working in series, with P-gp located subapically 
and Mrp situated basally. This might explain why downregulation of either 
transporter resulted in a similar modulation of opioid analgesia. Finally, 
Tzvetkov et al. (2013) showed that morphine uptake was fourfold increased in 
OCT1-overexpressing HEK293 cells and morphine uptake in human 
hepatocytes was reduced by 1-methyl-4-phenylpyridinium (MPP), an OCT 
inhibitor. Furthermore, the mean morphine AUC in OCT1 loss-of-function 
polymorphism carriers was significantly higher. 
As noted in chapter 2.2.4, morphine is mainly metabolized in phase II 
metabolism to water-soluble glucuronide conjugates M3G and M6G in the liver 
by UGT2B7 in humans and Ugt2b1 in rats. Interestingly, human brain 
homogenates have also been shown to metabolize morphine to its glucuronides, 
and the M3G:M6G ratio produced has been associated with the morphine 
concentration, so that higher morphine concentrations lead to a higher 
M3G:M6G ratio (Yamada et al., 2003). M6G is an attractive analgesic, but its 
BBB permeability is very poor, with a permeability that is 7.5 times less than 
that of morphine and equivalent to that of sucrose (Yoshimura et al., 1973). 
Bourasset et al. (2003) found that the brain uptake of M6G was not increased in 
P-gp- or Mrp1-deficient mice, but suggested M6G to be a substrate of the 
organic anion transporter (Oatp) 2, as the brain M6G concentration was 
decreased when Oatp2 substrates digoxin and PSC833 were co-perfused. Oatp2 
is known to exist on both the luminal and basolateral sides of the endothelium of 
the brain vasculature. Moreover, co-perfusion of D-glucose with M6G also led 
to decreased brain M6G, indicating that these compounds may use the same 
transporter, glucose transporter (GLUT) 1, expressed on the both sides of brain 
endothelial cells and used for facilitated diffusion of glucose to the brain. 
Interestingly, the binding of the opioid peptide enkephalin with β-D-glucose by 
an O-β-linkage has also been shown to enhance their brain access via the 
glucose transporter GLUT1 (Polt et al., 1994). Even less information exists on 
the transport of M3G, the main glucuronide metabolite formed in the Sprague-
Dawley rat. In microdialysis studies, Xie et al. (2000) demonstrated that 
probenecid, a typical Oatp inhibitor, increased the brain:blood ratio of M3G. 
Current knowledge of the possible BBB transporters for morphine and its 
metabolites is presented in Figure 8. 
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Figure 8. Current knowledge of the possible transporters associated with morphine, 
M6G, and M3G transport at the BBB. Morphine-associated transporters in black, M6G-
associated transporters in blue, and M3G-associated transporters in red. M3G, 
morphine-3-glucuronide; M6G, morphine-6-glucuronide; BBB, blood-brain barrier; 
Glut, glucose transporter; Mrp, multidrug resistance protein; Oatp, organ anionic 
transporter polypeptide; Oct, organic cation transporter; P-gp, P-glycoprotein. 
* The exact transporter and its location (basal or apical side of endothelium) are not 
known. 
2.4 Drugs used in the study 
2.4.1 Atipamezole, an alpha-2-adrenoceptor antagonist 
Atipamezole (4-[2-ethyl-2,3-dihydro-1H-inden-2-yl]-1H-imidazole) (Fig. 9) is 
an alpha-2-adrenoceptor antagonist (Scheinin et al., 1988; Virtanen, 1989). Its 
binding affinity for alpha-2 receptors (Ki = 1.6 nM) is approximately 100 times 
higher than for alpha-1 receptors (Haapalinna et al., 1997; Virtanen, 1989). It 
has affinity for alpha-2A-, alpha-2B-, and alpha-2C-adrenoceptor subtypes, and 
also for the alpha-2D human receptor variant (Haapalinna et al., 1997; 
Renouard et al., 1994). It has no affinity for opioid (mu and delta) receptors. 
However, in an in vivo situation, the increase in norepinephrine release in the 
Brain parenchyma 
Bloodstream 
P-gp 
Mrp 
Oct1 Oatp2 
Oatp2 
Glut1 
Glut1 
BBB  
endothelium 
Probenecid-sensitive 
transporter* 
Probenecid-sensitive 
transporter* 
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Review of the literature 
 
47 
CNS following the inhibition of alpha-2-adrenoceptors may result in the 
indirect activation of other systems (Haapalinna et al., 2000). 
 
Figure 9. Structural formula of atipamezole. 
 
In rodents, atipamezole is well tolerated. It is rapidly absorbed and distributed, 
and peak concentration levels in tissues are two- to threefold higher than the 
peak plasma concentration. Atipamezole undergoes first-pass metabolism and its 
elimination half-life is 1.3 hours. The LD50 for mice and rats is >30 mg/kg after 
i.p., s.c. or i.v. administration (Haapalinna et al., 1997; 1999). In human phase I 
studies, atipamezole was also well tolerated after a single dose (10–100 mg). 
After the largest dose, some subjective drug effects (e.g. motor restlessness, 
coldness, sweating, increased salivation) were reported. It also increased the 
plasma norepinephrine concentration and both the systolic and diastolic blood 
pressure. At the dose of 30 mg/subject, no subjective or cardiovascular side 
effects were reported (Karhuvaara et al., 1990).  
The majority of the brain noradrenergic neuron somas are based in the 
brainstem and medulla, and alpha-2-antagonists have extensive effects on the 
modulation of brain function. The locus coeruleus, the principal site for 
noradrenergic neurons, is affiliated with attention, memory, and learning 
(Berridge et al., 1993). Atipamezole, by stimulating endogenous norepinephrine 
release (presynaptic modulation), has potential effects on these parameters. The 
effects on cognitive performance have varied depending on atipamezole dose, 
stress experienced during the test, and the age of the animal. Low doses 
improved alertness, attention, planning, and recall of animals. At higher doses, 
the overactivation of the noradrenergic system has led to impairment in 
cognitive tasks; for a review, see Pertovaara et al. (2005). Atipamezole treatment 
has also shown promise in recovery after traumatic brain injury (Pitkänen et al., 
2004) and enhanced the positive effects and reduced the adverse effects of 
dopaminergic drugs used for the treatment of Parkinson’s disease (Haapalinna et 
al., 2003). 
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As the noradrenergic system has a role in modulating pain in both the brain and 
spinal cord (see 2.3.4), atipamezole has also been studied in various pain models. 
Supporting the hypothesis that the activity in the spinal descending 
noradrenergic pain regulatory pathways is low in non-painful conditions, 
atipamezole has not been shown to have effects in baseline nociceptive latencies 
(Pertovaara, 1993). In sustained nociception (formalin and capsaicin models), 
atipamezole administration antagonized the spinal descending noradrenergic 
pathways and increased the nociceptive responses (Green et al., 1998; Mansikka 
et al., 2004). At the brainstem level, however, microinjection of atipamezole 
produced antinociception in a neurogenic inflammation model (Mansikka and 
Idänpään-Heikkilä, 1996). Therefore, atipamezole may have two opposing 
mechanism of action regarding pain in different areas of the CNS. 
Interestingly, a recent study reported that intrathecal atipamezole (and 
other chemically distinct alpha-2-adrenergic antagonists) administered in 
ultralow doses increased the effect of morphine in thermal and mechanical 
nociception tests. The synergistic effect of atipamezole on morphine 
antinociception was seen at a dose (0.08 ng i.t.) lower than needed for blocking 
the spinal clonidine antinociception (5–10 µg i.t.). Atipamezole also inhibited 
the development of morphine tolerance and reversed the analgesic tolerance that 
had already developed (Milne et al., 2008; 2013). Clinically, alpha-2-agonists 
exert sedative and anesthetic properties, having similar effects to general 
anesthetics such as isoflurane. Currently, alpha-2-adrenoceptor agonists (e.g. 
medetomidine and dexmedetomidine) are in clinical use in both human and 
veterinary medicine. Atipamezole is registered for clinical use in veterinary 
medicine in several countries. It has proven effective in reversing the anesthesia 
induced by alpha-2-adrenoceptor activation by medetomidine. The animals are 
awake within minutes of administration of the antagonist, which is useful in 
minor veterinary surgical operations (Ewing et al., 1993; Jalanka, 1989; Vainio 
and Vähä-Vahe, 1990).  
2.4.2 Ibudilast, a phosphodiesterase inhibitor 
Ibudilast (3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine) (Fig. 10), also 
named AV411, MN-166, or KC-404, is used in Asia to treat bronchial asthma 
(Kawasaki et al., 1992), cerebrovascular disorders, and post-stroke dizziness 
(Armstead et al., 1988; Fukuyama et al., 1993; Shinohara and Kusunoki, 2002). 
These applications are based on the effect of ibudilast on tracheal smooth muscle 
contractility (Souness et al., 1994), cerebral blood flow improvement (Fukuyama 
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et al., 1993), and platelet aggregation (Kishi et al., 2000; Ohashi et al., 1986; 
Rile et al., 2001). The effects of ibudilast for its clinical implications are 
presumed to be related to PDE inhibition, which is key to the regulation of 
important second messengers, i.e. cAMP and cyclic GMP (cGMP). The 
inhibitory profile of ibudilast on human phosphodiesterases includes PDEs 3A, 
4, 10 and 11, with a lesser inhibition on other families (Gibson et al., 2006). In 
addition, ibudilast is a weak adenosine receptor antagonist, but other target 
proteins have not been identified (Ledeboer et al., 2006; 2007).  
 
  
Figure 10. Structural formula of ibudilast. 
 
In addition, ibudilast has anti-inflammatory properties in the CNS. In cultured 
glial cells, it suppressed LPS-induced production of inflammation markers TNF, 
IL-1 and IL-6, nitric oxide (NO) and reactive oxygen species concentration-
dependently, and increased the production of the anti-inflammatory cytokine 
IL-10 and neurotrophic factors GDNF and nerve growth factor (NGF) 
(Mizuno et al., 2004). It also decreased LPS-induced neuronal cell death in 
mouse neuron-glia co-cultures and glutamate-induced cell death in hippocampal 
neurons. The exact target protein for this effect of ibudilast on glial cells is not 
known. Inhibition of phosphodiesterases may additionally contribute to the anti-
inflammatory effects of ibudilast in the CNS (Sebastiani et al., 2006; Suzumura 
et al., 1999). Another potential mechanism of action is the inhibition of the 
proinflammatory macrophage migration inhibitory factor (MIF) (Cho et al., 
2010b). MIF is a proinflammatory cytokine itself (Alexander et al., 2012), but it 
is required for both IL-1 and TNF release and IL-1- and TNF-induced MAPK 
activation (Toh et al., 2006).  
Concerning opioid treatment, ibudilast was shown to attenuate morphine-
induced glial proinflammatory responses in rats (Hutchinson et al., 2009). 
Ibudilast also augmented the antinociceptive action of morphine and oxycodone 
in the tail-flick test without having noticeable effects of its own (Hutchinson et 
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al., 2009; Ledeboer et al., 2007). It attenuated chronic constriction injury (CCI) 
induced allodynia and was suggested to affect the development of opioid 
tolerance in CCI rats (Ledeboer et al., 2006). It has also been studied for the 
treatment of opioid dependency; for a review, see Coller and Hutchinson (2012). 
For a summary of findings on ibudilast in pain models, see Table 3.  
In phase 1 human studies, ibudilast was shown to be well tolerated as a 
single 30-mg oral dose, as well as in repeated administration (30 mg p.o. b.i.d.). 
Adverse events were minor. The mean elimination half-life was 19 h (Rolan et 
al., 2008). It is currently in clinical trials for the treatment of migraine, 
medication overuse headache, metamphetamine dependence, multiple sclerosis, 
and opioid withdrawal (http://www.clinicaltrials.gov, searched on May 1, 2014). 
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Table 3. Studies on ibudilast in different in vivo pain models. q.d., once daily; b.i.d., twice daily. 
Research model Outcome Dosing, route Other notes Reference 
POSITIVE FINDINGS 
CCI and SNL models, rat Alleviation of 
allodynia 
10 mg/kg i.p. b.i.d.;  
22 mg/kg p.o. b.i.d.; 
25 μg i.t. single dose 
Ibudilast is well distributed in the CNS 
Ibudilast tolerability was rather good with only transient 
changes in the neurobehavioral tests 
Ledeboer et al., 
2006 
Paclitaxel-induced allodynia, rat Alleviation of 
allodynia 
7.5 mg/kg i.p. b.i.d.  
Morphine tolerance in CCI, rat Attenuation of 
morphine tolerance 
7.5 mg/kg i.p. b.i.d.  
Acute morphine and oxycodone 
antinociception, rat 
Augmentation of 
opioid effect 
7.5 mg/kg i.p. Plasma morphine levels were not altered by ibudilast Hutchinson et al., 
2009 
Precipitated and spontaneous 
opioid withdrawal periods, rat 
Decrease in 
withdrawal behavior 
7.5 mg/kg i.p. b.i.d. along 
morphine treatment 
Morphine-induced dopamine 
release in nucleus accumbens, 
rat 
Decreased 
dopamine release 
7.5 mg/kg i.p. b.i.d. along 
morphine treatment 
Ibudilast also reduced withdrawal symptoms Bland et al., 2009 
Spinal cord injury, rat Decreased 
hyperalgesia 
10 mg/kg i.p.  
 
 Hama et al., 2012 
CCI model, rat Sciatic nerve TNF-alpha ê 
T13/L1 level dorsal root avulsion  Decreased central 
allodynia 
10 mg/kg s.c. q.d.  Ellis et al., 2014 
NEGATIVE FINDINGS 
CCI model, rat No effect 7.5 mg/kg p.o. Low oral bioavailability Ledeboer et al., 
2006 
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2.4.3 Spironolactone, a mineralocorticoid receptor antagonist 
Spironolactone (7α-acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone) 
(Fig. 11) is an old mineralocorticoid receptor antagonist with indications for the 
treatment of diseases associated with primary or secondary hyperaldosteronism 
(Doggrell and Brown, 2001). As it is a potassium-sparing diuretic, it can also be 
used to alleviate heart failure or to reduce ascites formation. Many patients 
diagnosed with acute heart failure or liver metastases are co-treated with 
spironolactone and morphine. For the management of treatment-resistant 
hypertension, the daily spironolactone doses are usually small, ranging from 12.5 
to 50 mg/day, but patients suffering from ascites due to cancer may be prescribed 
high doses of up to 400 mg/day (Ginès et al., 2004). In the rat, spironolactone 
has been reported to potentiate the cataleptic effect of morphine (Chu et al., 
1978). Possible mechanisms include the inhibition of efflux transporters leading 
to greater morphine disposition into the brain or the inhibition of morphine 
metabolism.  
 
Figure 11. Structural formula of spironolactone. 
 
Spironolactone has been shown to inhibit the production of TNF, IL-1, and 
several other proinflammatory cytokines in peripheral blood mononuclear cells. 
Whether this action is mediated by mineralocorticoid receptors is unknown. 
Spironolactone also shows promise in patients suffering from autoinflammatory 
diseases such as rheumatoid arthritis (Bendtzen et al., 2003; Hansen et al., 2004; 
Miura et al., 2006; Syngle et al., 2009). In an observational case series, 
spironolactone improved fibromyalgia-associated pain, stiffness, fatigue, 
depression, and mood (Wernze and Herdegen, 2014). Interestingly, 
spironolactone reversed corticosterone- and aldosterone-induced microglial 
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activation in vitro (Tanaka et al., 1997). In a cerebral stroke model (middle 
cerebral artery occlusion), the knockout of mineralocorticoid receptors led to 
reduced microglial activation and infarct volume (Frieler et al., 2011). 
Spironolactone also showed efficacy in the CCI neuropathic pain model (Jaggi 
and Singh, 2010) in peroral administration, and also when intrathecally 
administered in the chronic compression of the DRG model (Sun et al., 2012). 
In the same study, spironolactone decreased the expression and phosphorylation 
of the NMDA receptor, an important player in opioid tolerance and 
hyperalgesia. Interestingly, eplerenone, another more selective mineralocorticoid 
receptor antagonist, also reduced mechanical hypersensitivity in an inflamed 
DRG model (Dong et al., 2012), indicating that the mineralocorticoid receptors 
may play a role in the modulation of pain, probably via the inhibition of 
proinflammatory cytokine production (Chantong et al., 2012). The preclinical 
studies on spironolactone in different pain models are listed in Table 4.  
 Spironolactone inhibits human microsomal UGT2B7 (Knights et al., 
2010), and could thus also inhibit morphine glucuronidation. Even though there 
is no direct evidence for inhibition of the rat homologue Ugt2b1 by 
spironolactone, the genes encoding the two enzymes have a high gene sequence 
similarity (Tukey and Strassburg, 2000). In rodents, the disposition of morphine 
in the CNS is regulated by P-gp (Letrent et al., 1999; Schinkel et al., 1995; Xie 
et al., 1999), an efflux protein at the BBB. Inhibition of P-gp could lead to 
increased access of morphine to the CNS. Spironolactone has been reported to 
inhibit the transcellular transport of the P-gp substrate digoxin in P-gp-
overexpressing LLC-GA5-COL150 cells (Nakamura et al., 2001) and to 
increase the plasma concentration of the P-gp substrate digoxin in humans 
(Hedman et al., 1992), indicating a potential interaction with P-gp substrate 
drugs.  
Taken together, spironolactone possesses three properties that make it 
interesting for combining with morphine in the treatment of pain. First, it may 
suppress the pathological activation of glial cells via an unknown mechanism; 
second, it may inhibit the formation of the pronociceptive morphine metabolite 
M3G; and third, it may increase the access of morphine to the brain and delay 
its elimination by the inhibition of P-gp. 
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Table 4. Studies on spironolactone in different in vivo pain models. CCI, chronic constriction injury; CCD, chronic compression of the 
dorsal root ganglion; DRG, dorsal root ganglion. 
Pain model Outcome Dosing, route Other notes Reference 
POSITIVE FINDINGS 
Streptozotocin 
diabetes model, 
mouse 
Attenuation of hyperalgesia 7 or 15 mg/kg p.o.  Khan et al., 2009 
CCI, rat Attenuated CCI-related pain 
behavior 
10 and 20 mg/kg 
p.o. for 14 days 
Sciatic nerve TNF-alpha ê Jaggi and Singh, 
2010 
CCD, rat Attenuated CCD-related pain 
behavior 
3 μg i.t. b.i.d. Synergistic effects with glucocorticoid receptor 
antagonists 
Gu et al., 2011 
CCD, rat 
 
Attenuated CCD-related pain 
behavior 
3 μg i.t. b.i.d. Spinal microglial reactivity ê 
Concentrations of IL-1b and TNF-alpha in the spinal 
cord and DRGs ê 
NMDA receptor expression and phosphorylation ê 
Sun et al., 2012 
NEGATIVE FINDINGS 
CCI, rat No effect on hyperalgesia or 
allodynia 
3 μg i.t. b.i.d.  Wang et al., 2004 
Spinal morphine 
tolerance, rat 
No effect on development of 
morphine tolerance 
Co-treatment 3 μg 
i.t. b.i.d. 
 Lim et al., 2005 
Vincristine 
neuropathy, rat 
No alleviation of hyperalgesia 
or allodynia 
10 and 20 mg/kg 
p.o. for 14 days 
 Jaggi and Singh, 
2010 
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2.4.4 Ketamine, an N-methyl-D-aspartate receptor antagonist 
Ketamine [2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone] (Fig. 12) is a 
phencyclidine (PCP) derivative available as a racemic mixture and also as an S(+) 
enantiomer in Europe. It is highly lipophilic and easily crosses the BBB (White, 
1988). It is a general anesthetic that produces a state of dissociative anesthesia at 
high doses and analgesia at low doses (Sinner and Graf, 2008). The S-
enantiomer is a 2–4 times more potent anesthetic and analgesic than the R-
enantiomer (Arendt-Nielsen et al., 1996; Oye et al., 1992; White et al., 1980). 
The actions of ketamine are mainly based on noncompetitive antagonism of the 
NMDA receptor by binding to the PCP binding site (Fig. 5). Ketamine reduces 
the calcium influx and during a longer period modulates long-term potentiation, 
the wind-up phenomenon, and glutamate-mediated neurotoxicity. Ketamine has 
other possible interactions with sodium (Frenkel and Urban, 1992) and calcium 
channels (Sikand et al., 1995), the potassium/sodium hyperpolarization-
activated cyclic nucleotide-gated (HCN) 1 channel (Chen et al., 2009), as well 
as the nicotinic (Scheller et al., 1996), muscarinic (Hustveit et al., 1995), and 
opioid receptors (Finck and Ngai, 1982; Hirota et al., 1999; Hustveit et al., 
1995; Smith et al., 1980). 
 
 
Figure 12. Structural formula of ketamine. 
 
In humans, the elimination half-life of ketamine is two to three hours after oral 
administration and approximately 80% of the drug undergoes N-demethylation 
to norketamine by CYP3A4 and CYP2B6 enzymes (Hijazi, 2002; Sinner and 
Graf, 2008; Yanagihara et al., 2001). The bioavailability of ketamine is 17–24% 
in humans after oral administration (Chong et al., 2009; Clements et al., 1982). 
Norketamine and other metabolites are mainly excreted renally, and only small 
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amounts of ketamine are excreted unchanged (Geisslinger et al., 1993). 
Norketamine is an active metabolite of ketamine (Ebert et al., 1997; Holtman et 
al., 2008; Shimoyama et al., 1999). In a binding study, Ebert et al. (1997) 
reported that S-norketamine is an approximately five times weaker NMDA 
receptor antagonist than S-ketamine. Racemic norketamine was found 
antinociceptive in the rat (Holtman et al., 2008; Shimoyama et al., 1999) and it 
potentiated morphine antinociception in thermal, peripheral neuropathy, and 
tonic inflammatory pain models (Holtman et al., 2008). 
At low doses, ketamine has been proven efficacious as an analgesic 
perioperatively or in chronic pain states (Bell et al., 2005; Laskowski et al., 2011; 
Visser and Schug, 2006). Empirical evidence also indicates that ketamine 
coadministered with morphine can significantly increase the efficacy of 
morphine in cancer pain management. However, there has been little clinical 
research to support this (Bell, 2012). The majority of preclinical and human 
experimental studies (Arroyo-Novoa et al., 2011; Carstensen and Møller, 2010; 
Honarmand et al., 2012; Suppa et al., 2012) have focused on the 
pharmacodynamic properties of ketamine as an NMDA receptor antagonist 
leading to decreased opioid tolerance and hyperalgesia.  
Some preclinical research regarding the pharmacokinetic interaction 
between opioids and ketamine has been conducted. Pretreatment with ketamine 
caused cross-tolerance to morphine, but pretreatment with morphine caused an 
increase in the cataleptic response to ketamine. This finding was suggested to be 
caused by residual morphine in the brain after morphine treatment (Hance et al., 
1989). A similar effect was also observed with the use of sufentanil, fentanyl, 
alfentanil, nalbuphine, and butorphanol in combination with ketamine 
(Benthuysen et al., 1989).  Alfentanil infusion increased the brain concentration 
of ketamine and decreased its plasma AUC, indicating a greater distribution 
volume. On the other hand, the brain concentration of alfentanil was decreased 
in ketamine coadministration (Edwards et al., 2002). Interestingly, acute LPS 
treatment lowered plasma ketamine AUC and increased its elimination half-life, 
indicating an increase in BBB permeability and increased access of ketamine to 
the brain (Veilleux-Lemieux et al., 2012). In repeated administration, morphine 
may increase the permeability of the BBB (Sharma and Ali, 2006). This provides 
another interesting theory for the possibility of altered ketamine 
pharmacokinetics during chronic opioid administration. Regarding drug 
transporters, ketamine has not been identified as a substrate of P-gp (Doan, 
2002; Tournier et al., 2010) or Bcrp (Tournier et al., 2010), but an older study 
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(Ullrich et al., 1993) listed ketamine as a candidate substrate for both organic 
cation transporter (OCT) and organic anion transporter (OAT) families. In 
HEK293 cells transfected with human or rat OCT1, OCT2, and OCT3, 
ketamine was found to inhibit radiolabeled 1-methyl-4-phenylpyridinium 
uptake (Amphoux et al., 2006), a finding later confirmed by Massmann et al. 
(2013) regarding OCT3. 
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3. AIMS OF THE STUDY 
Drugs with different mechanisms of action such as ibudilast, atipamezole, 
spironolactone, and ketamine have shown promise in preclinical studies of 
offering new pain treatment possibilities. This study focused on these drugs by 
evaluating them in coadministration with morphine, the gold standard of 
opioids. The rat was used as the study subject. Studies were performed with 
special emphasis on both pharmacodynamic and pharmacokinetic properties of 
the studied drugs. 
 
The specific aims of this thesis study were: 
 
I. To investigate the antinociceptive and other nociception-
modulating properties of ibudilast alone and in coadministration 
with morphine; 
 
II. To assess the antinociceptive effects of ultralow doses of the 
alpha-2-adrenergic antagonist atipamezole as an adjuvant to 
morphine therapy in intrathecal and systemic administration; 
 
III. To determine the effects of the mineralocorticoid receptor 
antagonist spironolactone in acute coadministration with 
morphine and in morphine tolerance with special emphasis on 
potential pharmacokinetic interactions; 
 
IV. To assess the potential pharmacokinetic interactions between 
morphine and the NMDA receptor antagonist ketamine in acute 
and chronic morphine administration, with a focus on possible 
changes in brain drug and metabolite concentrations.  
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4. MATERIALS AND METHODS 
4.1 Ethical considerations 
The research procedures were conducted in accordance with the guidelines of 
the local authorities and the IASP (Zimmermann, 1983). The provincial 
government of Southern Finland had approved the study concept (Uudenmaan 
lääninhallitus, Hämeenlinna, Finland). For ethical reasons, the smallest possible 
number of animals and the smallest number of nociceptive tests per animal were 
used. In all nociceptive behavioral models, the animals were able to terminate 
the noxious stimulation. Cut-off latencies were used to avoid tissue damage. 
4.2 Materials 
4.2.1 Animals 
Male Sprague-Dawley rats (Harlan, Horst, Netherlands, and Scanbur, 
Sollentuna, Sweden) weighing 180–300 g at the beginning of experiments) were 
used. Rats were housed in plastic cages in light- and temperature-controlled 
rooms (artificial 12 h/12 h light–dark cycle, temperature 23 ± 2 ˚C). Water and 
standard laboratory chow were available ad libitum. For the behavioral studies, 
the rats were habituated to the testing environment 60–90 min/day for at least 
three days. Behavioral measurements were performed in a randomized and 
blinded fashion in all studies. After the experiments, the rats were euthanized by 
decapitation and brain, liver and serum samples were collected.  
4.2.2 Drugs 
Morphine hydrochloride, racemic ketamine hydrochloride (Ketaminol vet®, 
Intervet, Boxmeer, The Netherlands) and medetomidine hydrochloride 
(Domitor, Orion Pharma, Espoo, Finland) were purchased from the University 
Pharmacy (Helsinki, Finland). Ibudilast was purchased from APAC 
Pharmaceutical, LLC (Columbia, MD, USA), and atipamezole hydrochloride 
was provided by Orion Pharma (Espoo, Finland). Spironolactone and 
loperamide hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  
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Morphine and atipamezole were dissolved in physiological saline. Ibudilast was 
dissolved in 2% polysorbate 20 (Tween® 20; Fluka Chemika, Buchs, 
Switzerland) in physiologic saline. Spironolactone was diluted with 4% 
polysorbate 80 (Tween® 80, University Pharmacy, Helsinki, Finland) and 
loperamide with 2% polysorbate 80 in physiological saline. Ketamine and 
medetomidine were diluted to the administration concentrations with 
physiological saline. 
The injection volumes were 2 ml/kg subcutaneously and 10 ml/kg (Study 
I) or 5 ml/kg (Study III) intraperitoneally. In the intrathecal experiments, drugs 
were administered in separate phases using 50-µl Hamilton microsyringes in 
injection volumes of 10 µl. Between the drug phases, 1 µl of air was used to 
prevent ex vivo mixing of the solutions. Finally, 10 µl of saline was administered 
to flush the catheter.  
4.3 Methods 
4.3.1 Intrathecal cannulation 
The catheter implantation (Study II) was performed according to the modified 
method of Yaksh and Rudy (Yaksh and Rudy, 1976). Each rat was anesthetized 
with subcutaneous (s.c.) 0.4 mg/kg medetomidine (Domitor®, Orion Pharma, 
Espoo, Finland) and 60 mg/kg ketamine hydrochloride (Ketaminol vet®, 
Intervet, Boxmeer, The Netherlands). The rats were placed prone in a 
stereotactic frame, and the membrane of the cisterna magna was surgically 
exposed and punctured with care. A polyethylene cannula (8 cm, PE-10) was 
inserted through the opening and advanced caudally to the level of the lumbar 
enlargement. The cannula was fixed to the paravertebral muscles, and the skin 
was closed with 3-0 sutures. The cannula was then flushed with 0.9% saline. 
Rats showing any neurological symptoms such as movement of extremities or 
muscle twitches indicating potential CNS trauma leading to neurological deficits 
were immediately euthanized. Five days after cannulation, the placement of the 
cannula was verified by administering 10 µl of 10 mg/ml lidocaine intrathecally 
(Lidocain®, Orion Pharma, Espoo, Finland). Only rats with reversible 
symmetrical paralysis of both hindlimbs after injection were accepted for testing. 
To enable recovery from the cannulation operation and anesthesia, rats were 
allowed to rest for at least 8 days before any nociceptive tests.  
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4.3.2 Morphine tolerance treatment schemes 
In all studies, morphine tolerance was induced with a 4-day scheme. In studies I, 
II and III, the rats received 2 daily s.c. injections at 10:00 am and 8:00 pm. The 
individual doses were 10 mg/kg on day 1, 15 mg/kg on day 2, 20 mg/kg on day 3, 
and 30 mg/kg on day 4. In the intrathecal experiments in study II, rats received 
intrathecal injections of morphine twice daily for four days. The individual dose 
was 15 µg each day. In experiment IV, Alzet minipumps pumping 10 µl/h for 4 
days (model 2ML1, Durect, Cupertino, CA, USA) were used to provide a 
continuous morphine exposure. Under brief isoflurane anesthesia (induction in a 
chamber with 4–5% isoflurane at a flow rate of 1.5 l/min of air and maintenance 
with 2% at 1.5 l/min), a small incision was made between the scapulae of the rat 
and a subcutaneous pocket was created. The minipumps had been previously 
filled with vehicle or morphine hydrochloride to release 6 mg of morphine base 
per day. The pumps were installed subcutaneously and the wound was closed 
with 3-0 sutures.  
4.3.3 Pain measurement in acute nociception 
Hot plate tests (Woolfe and Macdonald, 1944) (Studies I–IV) were performed 
with a Harvard Apparatus Ltd hotplate apparatus (Edenbridge, Kent, United 
Kingdom). In the test, the rats were put onto a circular transparent plastic ring 
on the hot plate (52 ± 0.2 °C). Licking or brisk shaking of the hindpaw or 
jumping was considered a sign of thermal nociception. Latency to the first 
reaction was measured. To avoid tissue damage, the cutoff time was set to 60 
seconds. 
Tail-flick latencies (D’Amour and Smith, 1941) (Studies I–IV) were 
assessed with a Ugo Basile 37360 (Comerio, Italy) tail-flick apparatus. In the 
test, the rats were kept in hard plastic tubes covered with a dark cloth. After 
accustomization, an infrared beam (radiant heat) was directed in turn to three 
different points on the middle third of the tail of the test subject. The intensity 
was adjusted to produce a baseline latency of approximately 3.5 s. A flick of the 
tail was considered as a sign of thermal nociception and it automatically stopped 
the timer of the apparatus. The measurements were repeated three times at each 
time point, and the mean of the values was used as the result. To avoid tissue 
damage, the cutoff was set at 10 s. If an individual measurement reached the 
cutoff time, no further tests were performed for the particular time point.  
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The paw pressure test (Study II) (Randall and Selitto, 1957) was performed with 
the Ugo Basile paw pressure device (Comerio, Italy). Rats were gently wrapped 
in a towel during the test where the left hindpaw was placed under a pivot and 
the force applied to the paw was gradually increased. A brisk withdrawal of the 
hind paw terminated the measurement. A cutoff of 500 g was used. 
At each time point, the tail-flick test was performed first followed by the 
hot plate and/or paw pressure tests. A short waiting period was used between 
each test. The predrug (baseline) latencies were measured separately for each 
experiment day immediately before the administration of any drugs.  
4.3.4 Assessment of motor function 
A rotarod apparatus (Palmer electric recording drum; United Kingdom; 
diameter, 80 mm; speed, 27 rpm (Study I) and 12 rpm (Study IV)) was used to 
assess the actions of the test drugs on motor coordination. A rat was placed on 
the rotating rod, and the time the rat stayed there was measured. Training on 
the rod was allowed on three consecutive days. On the fourth day, animals that 
remained for at least 60 s on the rotating rod before drug administration were 
accepted to the test, and 60 s was also used as a cutoff time in the test proper. 
Possible effects of the drugs on spontaneous locomotor activity (Study I) 
were tested in a measurement box (70 × 70 × 35 cm; Kungsbacka Regler- & 
Mätteknik, Kungsbacka, Sweden) isolated from sound and light. Photocells were 
located at two different levels (2 and 12 cm) above the floor of the box to 
automatically detect movements of the animal. A 30-min measurement period 
was started 15 min after the drug injections. 
4.3.5 Drug concentration measurements 
The drug concentrations of morphine, M3G, M6G, normorphine (Study III), 
and ketamine and norketamine (Study IV) were determined with LC-MS/MS 
(liquid chromatography-tandem mass spectrometry) analyses as previously 
described (Zheng et al., 1998) with some modifications. An Agilent 1100 series 
high performance liquid chromatography (HPLC) system (Agilent 
Technologies, Waldbronn, Germany) coupled to an API 3000 tandem mass 
spectrometer (AB Sciex, Toronto, ON, Canada) operating in a positive turbo 
ion spray mode was used. The chromatographic separation was achieved on an 
Atlantis HILIC Silica column (3 µm particle size, 2.1 × 100 mm I.D.) (Waters, 
Milford, MA, USA) using a gradient elution of the mobile phase consisting of 
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acetonitrile with 10 mmol/l ammonium formate in 0.2% formic acid (v/v) (Study 
III) or 20 mmol/l ammonium acetate (pH 3.0, adjusted with formic acid) (Study 
IV). An aliquot (7 µl, Study III; 5 µl, Study IV) was injected at a flow rate of 
250 µl/min (Study III) or 200 µl/min (Study IV) to give a total chromatographic 
run time of 18 min (Study III) or 24 min (Study IV). Oxycodone served as an 
internal standard for morphine and its metabolites. Deuterium-labeled internal 
standards were used for ketamine and norketamine (Study IV). The following 
ion transitions were monitored: morphine, m/z 286 to m/z 152; M3G and M6G, 
m/z 462 to m/z 286; normorphine, m/z 272 to m/z 152; and oxycodone, m/z 
316 to m/z 241. The limit of quantification was 1.0 ng/ml for morphine, M3G, 
and M6G, and 0.5 ng/ml for ketamine and norketamine. A signal-to-noise ratio 
(S/N) of 20:1 was used as the limit of detection for normorphine, and the 
quantities were given in arbitrary units relative to the ratio of the peak area of 
normorphine to that of the internal standard. The day-to-day coefficients of 
variation (CV) were below 15% at relevant concentrations for all analytes. 
4.3.6 Experimental design of Studies I–IV 
The experimental designs of the studies are described in brief in Table 5 and in 
detail in the original publications (Studies I–IV, Methods). 
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Table 5. Designs of studies I-IV in brief. 
 
Question addressed Experimental design Methods used 
 
Study I 
  
• Antinociceptive effects of ibudilast 
alone or in combination with 
morphine 
Ibudilast with or without morphine 
administered to drug-naïve animals 
Tail-flick 
Hot plate 
• Effects of ibudilast coadministration 
on the development of morphine 
tolerance 
• Effects of ibudilast on morphine 
withdrawal 
Ibudilast co-treatment with the morphine 
tolerance scheme for four days; nociceptive 
tests on day 5; observations of weight 
change during withdrawal 
Tail-flick 
Hot plate 
• Effects of acute coadministration of 
ibudilast and morphine in morphine-
tolerant animals 
• Effects of ibudilast on opioid tolerance 
in already developed tolerance 
Morphine tolerance treatment protocol, 
drug coadministration and nociceptive 
tests on day 5, continuation of drug 
coadministration and repeated nociceptive 
tests on day 9  
Tail-flick 
Hot plate 
• Effects of ibudilast on motor 
coordination or spontaneous 
locomotor activity 
Ibudilast alone and in coadministration 
with morphine 
Rotarod 
Locomotor 
boxes 
 
Study II 
  
• Effects of subcutaneously 
administrated low-dose atipamezole 
on subcutaneous morphine 
antinociception 
Morphine combined with three 
atipamezole doses 
Tail-flick 
Hot plate 
• Effects of subcutaneously 
administrated low-dose atipamezole 
on subcutaneous morphine 
antinociception in opioid tolerance 
Morphine combined with three 
atipamezole doses in opioid-tolerant 
animals 
Tail-flick 
Hot plate 
• Effects of intrathecally administered 
low-dose atipamezole on intrathecal 
morphine antinociception 
Morphine combined with three 
atipamezole doses 
Tail-flick 
Paw pressure 
• Effects of intrathecally administered 
low-dose atipamezole on intrathecal 
morphine antinociception in opioid 
tolerance 
Morphine combined with three 
atipamezole doses in opioid-tolerant 
animals 
Tail-flick 
Paw pressure 
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(Table 5 continued) 
Question addressed Experimental design Methods used 
 
Study III 
  
• Effects of systemical spironolactone on 
morphine-induced antinociception 
Two doses of morphine 
combined with spironolactone 
Tail-flick 
Hot plate 
• Effects of acute morphine with or 
without spironolactone in morphine-
tolerant rats 
• Effects of repeated spironolactone 
administration on morphine-induced 
tolerance 
Four-day morphine tolerance 
scheme with or without 
spironolactone cotreatment 
followed by drug 
coadministration on day 5 
Tail-flick 
Hot plate 
• The concentrations of morphine and its 
metabolites in the brain, liver, and serum 
after morphine and spironolactone 
coadministrations 
Morphine combined with one or 
two doses of spironolactone in 
opioid-naïve rats 
Tail-flick 
Hot plate 
High performance 
liquid chromatography 
• Effects of  spironolactone on the 
antinociceptive properties of 
loperamide, a peripherally restricted P-
glycoprotein substrate opioid 
Loperamide combined with 
spironolactone in opioid-naïve 
rats 
Tail-flick 
Hot plate 
 
Study IV 
  
• Effects of acute small dose of ketamine 
on morphine antinociception and tissue 
ketamine, norketamine and morphine 
concentrations in opioid-tolerant 
animals 
Preceding morphine pump 
treatment for four days; 
administration of ketamine on 
day 5  
Tail-flick 
Hot plate 
Rotarod 
High performance 
liquid chromatography 
• Effects of acute small dose of ketamine 
on morphine antinociception and tissue 
ketamine, norketamine and morphine 
concentrations in opioid-tolerant 
animals under withdrawal 
Removal of morphine pumps 
after day 5, withdrawal for two 
days, acute doses of ketamine 
and/or morphine on day 7 
Tail-flick 
Hot plate 
Rotarod 
High performance 
liquid chromatography 
• Effects of ketamine and/or morphine 
administration on observed 
antinociception and drug tissue 
concentrations 
Acute tests using small doses of 
morphine and/or ketamine 
Tail-flick 
Hot plate 
Rotarod 
High performance 
liquid chromatography 
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4.4 Statistical analysis 
The hot plate and tail-flick results are expressed as a percentage of the maximum 
possible effect (MPE%), calculated as MPE% = [(postdrug latency – baseline 
latency)/(cutoff time – baseline latency)] × 100%, which takes into account the 
differences in baseline nociceptive latencies. In the text and figures, results are 
presented as means of the groups (± SEM). The behavioral data were tested for 
statistically significant differences in mean values by two-way analysis of variance 
(ANOVA) followed by a Bonferroni correction for multiple comparisons (group 
× dose or group × time) (Studies I and II) or followed by a Holm-Sidak 
correction for multiple comparisons (group × dose or group × time) (Studies III 
and IV). For the concentration data in Studies III and IV, a two-tailed t-test or 
one-way analysis of variance followed by the Holm-Sidak correction was used. 
For the nonparametric rotarod test data (Study IV), the Kruskal-Wallis test 
followed by Dunn’s multiple comparison was used. The difference was 
considered significant at P < 0.05 in both the analysis of variance and the post hoc 
test. The data were analyzed using GraphPad Prism, versions 4.0c (Study I), 
5.0b (Study II), 6.0a (Study III), and 6.0c (Study IV) for Macintosh (GraphPad 
Software, Inc., San Diego, CA, USA). 
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5. RESULTS 
5.1 Morphine 
5.1.1 Effects of morphine in different models of nociception 
Morphine was used as the study opioid in all studies. The peak antinociception 
was measured at 30 minutes after s.c. administration, when it had an ED50 of 3.1 
mg/kg in the tail-flick test and 3.7 mg/kg in the hot plate test (Study III) (Fig. 
13). After i.t. administration, 1.5 µg morphine was needed to produce over 50% 
MPE. The peak antinociception was measured at 30 min in both the tail-flick 
and paw pressure tests (Study II, Fig. 1). 
 
 
Figure 13. ED50 graphs for morphine in the tail-
flick and hot plate tests 30 minutes after 
subcutaneous administration. n = 8. 
 
 
 
 
 
The tissue concentrations of morphine and their corresponding antinociceptive 
responses were determined (Study III). After 4 mg/kg of s.c. morphine, 
significant antinociception was observed in the tail-flick test at 30 and 90 
minutes after administration and in the hot plate test at 30 min after 
administration (Fig. 14A and B). The brain morphine concentrations were 406 
± 22 nmol/kg and 258 ± 9 nmol/kg at 30 and 90 minutes, respectively (n.s.). In 
serum, the morphine concentration at 90 min was significantly lower than at 30 
min (2000 ± 210 nmol/l vs. 410 ± 22 nmol/l, P < 0.001) (Fig. 14C). 
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Figure 14. Antinociceptive properties of subcutaneous 4 mg/kg morphine (Mo) in the 
tail-flick (A) and the hot plate (B) tests and its corresponding serum and brain 
concentrations (C). *** P < 0.001 compared with the vehicle group. ### P < 0.001 
between the timepoints. n = 5–10. 
 5.1.2 Development of morphine tolerance in different models 
A 4-day scheme for inducing morphine tolerance was used both in s.c. and i.t. 
models. On day 5, morphine-tolerant and morphine-naïve rats received 5 mg/kg 
(Studies I and II) and 4 mg/kg (Study III) s.c. morphine as the test dose, which 
resulted in significant antinociception in morphine-naïve rats, whereas only 
minor (n.s.) antinociception was observed in morphine-pretreated rats (Table 6). 
In the i.t. model, the test dose was 1.5 µg (Study II).  
In Study IV, osmotic minipumps delivering a steady dose of morphine 
were used. After 24 hours of minipump implantation, significant antinociception 
was observed. Tolerance to morphine antinociception developed on the fifth day 
of pump treatment (Study IV, Fig. 2).  
In Studies I–IV, no opioid-induced hyperalgesia (reduction of nociceptive 
thresholds below baseline after morphine administration) was observed (Lilius et 
al., unpublished finding). 
In Study III, brain morphine concentrations were measured 90 min after 
an acute 8 mg s.c. dose in morphine tolerant and morphine-naïve rats. No 
difference in the mean brain morphine concentration was observed (202 ± 8 ng/g 
in tolerant rats vs. 200 ± 10 ng/g in naïve rats, n = 4–8) (Lilius et al., 
unpublished data). 
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Table 6. Antinociceptive effects of a test dose of morphine (Mo) administered after 
the induction of morphine tolerance. B.i.d., twice daily; MPE%, percentage of the 
maximum possible effect; TF, tail-flick; HP, hot plate; n/a, data not available.  
* Statistically significant difference compared with the vehicle-administered group. n 
= 7–8. 
 
5.2 Ibudilast (Study I) 
5.2.1 Antinociceptive effects of ibudilast 
Antinociception was assessed with the tail-flick (Fig. 15A) and hot plate (Fig. 
15B) tests after the administration of four different doses of ibudilast with or 
without morphine to drug-naïve rats. An antinociceptive effect of ibudilast 
administered alone at doses of 7.5 and 22.5 mg/kg i.p. was observed. Morphine 
2.5 mg/kg s.c. caused significant antinociception in both tests, and ibudilast and 
morphine had an additive effect in the tests.  
In a separate experiment, at 30 minutes after drug administrations, 
ibudilast (22.5 mg/kg i.p.) did not modify the mean brain concentrations of 
morphine (4 mg/kg s.c.) (Lilius et al., unpublished data). 
 
   TF latency after test 
dose (MPE%) 
HP latency after test 
dose (MPE%) 
Study Dosing Test dose  Mo-naïve Tolerant Mo-naïve Tolerant 
I s.c. b.i.d. 5 mg/kg s.c. 81* 26 71* 7 
II s.c. b.i.d. 5 mg/kg s.c. 98* 34 83* 21 
III s.c. b.i.d. 4 mg/kg s.c. 56* 18 34* 0 
II i.t. b.i.d. 1.5 μg i.t. 53* 22 n/a n/a 
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Figure 15. The antinociceptive dose–response curve for ibudilast in the tail-flick (A) 
and hot plate (B) tests with or without 2.5 mg/kg s.c. morphine at 30 minutes after 
administration. The mean of the maximum possible effect (MPE%) ± SEM 
is plotted. For the ibudilast groups: *, ** Statistically significant difference (P < 0.05, P 
< 0.01, respectively) compared with the group that was given the vehicle alone. For 
the morphine groups: # Statistically significant difference (P <   0.05) compared with 
the group that was given morphine without ibudilast. § Statistically significant 
difference (P < 0.05) compared with the group that was given the same dose of 
ibudilast without morphine. n = 7. 
5.2.2 Effects of ibudilast cotreatment on the restoration of morphine 
antinociception 
Ibudilast was studied in several models of opioid tolerance. The exact treatment 
schemes are presented in Study I, Table 1. When ibudilast was acutely 
coadministered with morphine to opioid-tolerant rats on day 5, it restored the 
antinociceptive effect of morphine in the tail-flick test (Fig. 16). However, in the 
hot plate test, ibudilast had antinociceptive effects of the same magnitude in 
opioid tolerant rats as in naïve animals (Study I, Fig. 5).  
From this point, the cotreatment of morphine and ibudilast twice daily 
was continued for four more days and the rats were retested on day 9 after drug 
coadministration. Morphine alone produced no significant antinociception, but 
ibudilast 7.5 mg/kg i.p. combined with morphine enhanced morphine 
antinociception without having antinociceptive effects of its own (Study I, Fig. 
6).  
Results 
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Figure 16. Effects of acute ibudilast treatment on morphine antinociception in 
morphine-tolerant rats in the tail-flick test. Morphine tolerant rats were given two 
different doses of ibudilast and/or a test dose of morphine. The mean of the 
maximum possible effect (MPE%) ± SEM is shown. *, P < 0.05 compared with the 
vehicle. #, P < 0.05 compared with the morphine-tolerant, morphine-administered 
group (black bar). §, P < 0.05 between selected groups. 
 
In a separate experiment, three different doses of ibudilast (0.83, 2.5 and 7.5 
mg/kg) administered to rats twice daily under the four-day morphine tolerance 
scheme to assess the potential of ibudilast in inhibiting the development of 
morphine antinociceptive tolerance. However, in the hot plate test, pretreatment 
with 7.5 mg/kg ibudilast increased the development of tolerance to an acute test 
dose of 5 mg/kg morphine (Study I, Fig. 2B). 
5.2.3 Effects of ibudilast on motor coordination 
As ibudilast showed sedative effects in routine handling of the rats, the effects of 
acutely administered ibudilast were investigated in a measurement box 
measuring spontaneous locomotor activity in a novel environment. The rats were 
placed inside the box 15 min after drug administration for a total of 30 minutes. 
At doses of 2.5 and 7.5 mg/kg i.p., compared with vehicle, ibudilast significantly 
reduced spontaneous locomotor activity during the 30-min observation period 
(Fig. 17A). In a separate experiment, rats first received a 4-day pretreatment of 
20 mg/kg i.p. ibudilast twice daily and locomotor experiments were conducted 
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on day 5, demonstrating that no tolerance to the observed effect had developed 
(Lilius et al., unpublished data, Fig. 17B). 
 
0-5 5-10 10-15 15-20 20-25 25-30
0
100
200
300
400
500
600
Time (min)
A
ct
iv
it
y 
co
un
ts
Vehicle
Ibudilast 2.5 mg/kg i.p.
Ibudilast 7.5 mg/kg i.p.
***
*** ** *****
***
***
*** *** ***
A
  
Figure 17. Effects of acute ibudilast (A) and ibudilast pretreatment (B) on spontaneous 
locomotor activity. The activity counts (number of photocell crossings in 5-min 
periods) over time ± SEM are shown 15 min after drug administration. *, **, *** 
Statistically significant difference (P < 0.05, P < 0.01, P < 0.001, respectively) compared 
with the vehicle group. n = 6. 
 
The effects of ibudilast on motor coordination were also examined using the 
rotarod test. On the first treatment day, all rats (100%) that had received vehicle 
achieved the cutoff time (60 s) at 30 and 120 min. Ibudilast i.p. in doses of 0.83 
and 2.5 mg/kg caused no significant differences (52.3 ± 7.7 and 53.0 ± 7.0 s, 
respectively) compared with vehicle. After administration of 7.5 mg/kg ibudilast, 
the mean survival time was reduced to 11.2 ± 4.0 s at 30 min and 31.5 ± 12.6 s at 
120 min (P < 0.05 compared with vehicle). These measurements were repeated 
on day 4 after three preceding days of ibudilast treatment (0.83, 2.5, and 7.5 
mg/kg i.p. twice daily), and the same significant results were achieved as on day 
1, indicating that tolerance to the observed effect did not develop during four 
days of treatment (Study I, Results). 
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5.3 Atipamezole (study II) 
5.3.1 Effects of atipamezole coadministration in acute morphine antinociception 
The choice of the initial intrathecal morphine dose was based on pilot 
experiments, in which 1.5 µg of morphine produced approximately 50 MPE% in 
the tail-flick test. The studied ultralow i.t. doses of atipamezole did not produce 
antinociception in any of the nociceptive tests on their own. 
Morphine was administered in the same syringe in a separate phase with 
different doses of atipamezole (0.01, 0.1 and 1 ng) or vehicle (Fig. 18). 
Morphine alone produced significant antinociception at 30 (P < 0.05) and 60 
min (P < 0.01) after drug administration. Morphine combined with 1 ng 
atipamezole produced significantly greater antinociception than the combination 
of morphine and vehicle 30 minutes after drug administration in the tail-flick 
test (P < 0.05). However, a longer-lasting effect of the drug combination was not 
observed. In the paw pressure test, morphine alone produced significant 
antinociception from 15 to 120 minutes after administration, but atipamezole 
did not augment this effect (Study II, Results). In further studies, intrathecal 
morphine doses of 0.5 and 5 µg produced significant antinociception at 30 and 
60 min, but the 1-ng dose of intrathecal atipamezole did not have an additive 
effect on the observed antinociception (Study II, Results). 
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Figure 18. Effects of intrathecal atipamezole on intrathecal morphine antinociception 
in the tail-flick test. Rats were administered three different doses of atipamezole (At) 
or vehicle (Veh) with morphine (Mo) 1.5 μg. The mean of the maximum possible effect 
(MPE%) ± SEM is plotted as a function of time. * Statistically significant difference (P < 
0.05) compared with the group that was administered morphine and vehicle. n = 6–7, 
except n = 4 in the vehicle group. 
 
5.3.2 Effects of spinal atipamezole coadministration in morphine tolerance 
Spinal morphine tolerance was induced during four days by administering 15 µg 
of intrathecal morphine twice daily. On day 5, in the tail-flick test, intrathecal 
1.5 µg morphine produced significant antinociception at 30 and 60 minutes (P < 
0.001 and P < 0.01, respectively) (Fig. 19), whereas the same dose in morphine-
pretreated animals did not cause significant antinociception compared with 
vehicle. At the intrathecal dose of 10 ng but not 1 ng, atipamezole 
coadministered with morphine partly restored morphine antinociception at 30 
minutes (P < 0.05).  
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Figure 19. Effects of intrathecal atipamezole on intrathecal morphine antinociception 
in the tail-flick test in morphine-tolerant rats. Morphine-tolerant rats were 
administered two different doses of atipamezole (At) or saline (Sal) with morphine 
(Mo) 1.5 μg. As a control, morphine was also administered to previously morphine-
naïve animals. The mean of the maximum possible effect (MPE%) ± SEM is plotted as a 
function of time. *, **, *** Statistically significant difference (P < 0.05, P <0.01, P < 
0.001 respectively) compared with the morphine-tolerant group that received acute 
morphine only. n = 6–9. 
 
5.3.3 Effects of systemic administration of atipamezole with morphine 
As systemic administration is the preferred route for the ease of drug use, the 
effects of systemic atipamezole on systemic acute morphine antinociception and 
morphine tolerance were also evaluated. Because in the pilot experiments 
atipamezole doses of 30 and 300 µg/kg s.c. induced motor restlessness, the 
atipamezole doses chosen were 0.03, 0.3, and 3 µg/kg s.c. Morphine 2.5 mg/kg 
s.c. produced significant antinociception in the tail-flick test 30 min after 
administration (P < 0.05) and in the hot plate test at 30, 75, and 120 minutes (P 
< 0.05 at all time points and P < 0.001 at 75 minutes). In acute tests, however, 
none of the coadministered atipamezole doses significantly increased the effect 
of morphine in either of the tests (Study II, Results).  
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5.4 Spironolactone (Study III) 
5.4.1 Effects of spironolactone in acute morphine antinociception and morphine 
tolerance 
Spironolactone 50 mg/kg i.p. had no antinociceptive effects of its own, but it 
increased the antinociceptive potency of 2.5 and 5.0 mg/kg of s.c. morphine in 
both the tail-flick and hot plate tests (Study III, Fig. 1). In morphine-tolerant 
rats, the magnitude of increased antinociception observed was at the same level 
as in naïve animals (Study III, Fig. 2).  
Chronic spironolactone pretreatment alone (50 mg/kg i.p. twice daily for 
four days) did not affect antinociception by acute morphine alone. To study the 
effects of spironolactone treatment on the development of morphine tolerance, 
one group of the morphine tolerance-treated rats was cotreated twice daily with 
50 mg/kg i.p. spironolactone, and acute 4 mg/kg s.c. morphine alone was given 
on day 5. Antinociception observed in cotreated animals was minimal and did 
not differ from rats that had received the morphine tolerance treatment without 
spironolactone (Study III, Results). 
5.4.2 Effects of spironolactone on morphine and morphine-3-glucuronide 
concentrations in the brain 
In acute coadministration, spironolactone administered 60 min and 0 min before 
morphine 4 mg/kg s.c. significantly increased morphine antinociception at 30 
and 90 min (Fig. 20A). In the brain, coadministration increased the mean 
morphine concentration by 69% and 290% at 30 and 90 min, respectively (Fig. 
20B). At 30 minutes, serum morphine concentrations were essentially at the 
same level, but the liver concentrations were increased in the group that was 
coadministered two doses of spironolactone (Fig. 20C and D). Continuing to 90 
minutes, morphine concentrations in all tissues were elevated in the presence of 
spironolactone. Spironolactone did not, however, reduce the formation of M3G 
in the liver (Study III, Fig. 3G). 
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Figure 20. Effects of 50 mg/kg i.p. spironolactone treatment 60 min before morphine 
(SPR 50) or 60 min before and coadministered with morphine (SPR 50 x 2) in the hot 
plate test 30 and 90 min after morphine administration (A). The mean of the 
maximum possible effect (MPE%) ± SEM is shown. The corresponding brain (B), serum 
(C), and liver morphine concentrations (D) are presented (mean ± SEM). *, *** 
Statistically significant difference (P < 0.05, P < 0.001, respectively) compared with the 
vehicle-administered group. #, ##, ### Statistically significant difference (P < 0.05, P < 
0.01, P <0.001, respectively) between the selected groups. MO, morphine. n = 10 at 30 
min and n = 5 at 90 min in behavioral experiments; n = 5 per timepoint in 
concentration studies. 
5.4.3 Antinociceptive effects of the P-glycoprotein substrate loperamide 
combined with spironolactone 
To assess the effects of spironolactone on BBB transporter proteins, 
spironolactone (50 mg/kg i.p.) was administered 60 minutes before and 
concomitantly with a peripheral opioid, P-gp substrate loperamide (10 mg/kg 
s.c.). In coadministration, loperamide showed significant antinociceptive 
30 90
0
50
100
Time after treatment (min)
H
ot
 p
la
te
 la
te
nc
y 
(M
PE
%
)
A
***
***
******
###
###
*
###
30 90
0
100
200
300
400
Time after treatment (min)
M
O
 c
on
ce
nt
ra
ti
on
 (n
g/
g)
B
##
###
###
#
BRAIN
30 90
0
200
400
600
800
Time after treatment (min)
M
O
 c
on
ce
nt
ra
ti
on
 (n
g/
m
l)
C
#####
SERUM
30 90
0
200
400
600
800
Time after treatment (min)
M
O
 c
on
ce
nt
ra
ti
on
 (n
g/
g)
D
#
# ##
LIVER
VEH + VEH
MO 4 + VEH
MO 4 + SPR 50
MO 4 + SPR 50 × 2
Results 
 
78 
properties in the hot plate test 30 and 90 minutes after administration, 
indicating potential changes in the drug transporter function of the BBB 
induced by spironolactone (Study III, Fig. 4).  
5.5 Ketamine (Study IV) 
5.5.1 Ketamine coadministration to morphine-tolerant rats leads to increased 
brain concentrations of morphine, ketamine, and norketamine  
The effects of ketamine in morphine tolerance have been suggested to be 
mediated via a pharmacodynamic interaction. In this study, the possibility of a 
pharmacokinetic interaction between the drugs was investigated. Subcutaneous 
minipumps delivering morphine 6 mg/day induced tolerance (Study IV, Fig. 2), 
and on day 5 rats received a small dose of ketamine (10 mg/kg s.c.). In 
morphine-naïve rats, ketamine caused no antinociception, whereas in morphine-
tolerant rats it caused significant antinociception, peaking at 90 minutes (54 
MPE% increase, Fig. 21A and B). In the rotarod test, ketamine induced motor 
dysfunction at 30 min and the effect was enhanced by the chronic morphine 
treatment. At peak antinociception, however, the rotarod performance of all 
groups had returned to normal (Fig. 21C).  
In morphine-tolerant ketamine-treated rats, the mean morphine, 
ketamine and norketamine brain concentrations were 2.1-, 1.4-, and 3.4-fold 
higher, respectively, compared with the rats that received the morphine tolerance 
treatment or ketamine only (Fig. 19). In the liver of morphine-tolerant 
ketamine-treated rats, the mean ketamine concentration was six-fold higher and 
the norketamine concentration two-fold higher than in morphine-naïve rats. 
Hence, morphine tolerance affects the pharmacokinetic properties of ketamine, 
while on the other hand, acute ketamine affects the pharmacokinetic properties 
of morphine.  
In a separate experiment, the effect of morphine withdrawal on morphine 
and ketamine drug concentrations was investigated. The morphine pump 
treatment lasted for 5 days, after which the pumps were removed. On day 7, the 
rats were administered the same low ketamine dose (10 mg/kg s.c.). As noted on 
day 5, during withdrawal ketamine and norketamine concentrations were also 
increased, although significantly only in the liver (Study IV, Fig. 4). 
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5.5.2 Effects of combined ketamine and morphine in acute models of nociception 
As ketamine administered to morphine-tolerant rats caused notable increases in 
the brain concentrations of both ketamine and morphine, it was of interest 
whether this interaction would also be observable in an acute experiment. 
Morphine (2.5 mg/kg s.c.) was administered 15 minutes before ketamine (10 
mg/kg s.c.). In behavioral experiments, the coadministration of morphine and 
ketamine caused significant motor coordination impairment compared with 
morphine only at 30 min, which was also reflected in the results of the hot plate 
test (Study IV, Fig. 5A–C). Morphine coadministration had no effect on 
ketamine or norketamine brain concentrations 90 min after ketamine 
administration, but ketamine slightly increased the mean morphine 
concentration in the brain and liver (Study IV, Fig. 5D–I).  
 
 
 
 
 
 
Figure 21 (next page). Effects of an acute small dose of ketamine on antinociception 
in morphine-tolerant rats. Rats undergoing s.c. morphine (6 mg/day, Mo) or vehicle 
(Veh) pump treatment were administered an acute s.c. dose of ketamine (10 mg/kg, 
Ket) or vehicle (Veh) on day 5. Antinociception was measured using tail-flick (A) and 
hot plate (B) tests. The mean of the maximum possible effect (MPE%) ± SEM is plotted. 
In the rotarod test (C), the mean (± SEM) survival time (seconds) is plotted. From 
separate animals with the same pretreatments, whole brain, serum, and liver samples 
were collected 90 min after ketamine administration. The concentrations of the 
experimental drugs and their main metabolites (MO, morphine; M3G, morphine-3-
glucuronide; KET, ketamine; NORKET, norketamine) were quantified. The mean tissue 
concentrations (± SEM) are plotted in graphs D–I. The increase or decrease in tissue 
concentrations between the treatment groups is shown in percentages for each 
substance. n = 7–8. **, *** Statistically significant differences (P < 0.01, P < 0.001, 
respectively) compared with the vehicle control group. #, ##, ### Statistically 
significant differences (P < 0.05, P < 0.01, P < 0.001, respectively) compared with the 
morphine-pump-treated group that received acute vehicle. §§, §§§ Statistically 
significant differences (P < 0.01, P < 0.001, respectively) compared with the vehicle-
pretreated group that received acute ketamine. 
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6. DISCUSSION 
6.1 Methodological considerations 
The use of animals for the study of pain is necessary and justified because of the 
complex pain and nociception processing systems. Studies on the complex 
processing of nociception and pain require a neuronal network with the 
supraspinal parts of the CNS. The struggle to alleviate pain and suffering and to 
improve existing pain remedies is one of the most important and humane areas 
of scientific research. Current animal models used for the study of pain have 
proven invaluable when they are used carefully and with attention to supporting 
data from in vitro, in silico, and other methods (Mogil et al., 2010). In the future, 
when evaluating changes (i.e. synaptic plasticity and potential glial activation) in 
the CNS during opioid treatment, the development of noninvasive imaging 
techniques such as magnetic resonance imaging may especially help in reducing 
the number of animals needed and also enable more versatile studies in humans. 
All animal treatment procedures of this study were carefully conducted following 
the guidelines of local authorities and the IASP (Zimmermann, 1983). The 
suffering of the animals was minimized and the number of animals used was 
reduced by using a washout period when applicable. 
Of the thermal nociceptive tests used, the hot plate test reflects 
supraspinal antinociception, whereas the tail-flick reaction is a spinal reflex. Both 
of these are widely used and have been found predictive in opioid research (Le 
Bars et al., 2001). For the intrathecal experiments (Study II), the method for 
measuring spinal nociception was extended to also cover mechanical nociception 
measured by the Randall-Sellitto paw pressure test.  
6.2 Ibudilast in coadministration with morphine 
Study I demonstrated that ibudilast restored the antinociceptive effect of 
morphine in developed morphine tolerance after single and repeated 
administration. However, when ibudilast treatment was given together with the 
morphine tolerance treatment, the development of tolerance could not be 
attenuated.  
Previous studies (Hutchinson et al., 2009; Ledeboer et al., 2007) have 
demonstrated the ability of ibudilast to augment morphine and oxycodone 
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antinociception. However, in these studies, the administration of ibudilast alone 
at a dose of 7.5 mg/kg i.p. was reported not to produce any change in hind paw 
or tail-flick latencies over a 100-minute time course after administration 
(Hutchinson et al., 2009). In Study I, already the 7.5-mg/kg dose of ibudilast 
caused a marginal (significant in one experiment) increase in the tail-flick, but a 
marked increase in hot plate latencies 30 and 120 min after acute administration. 
As the hot plate test involves supraspinal nociceptive processing (Le Bars et al., 
2001), it may be more sensitive to unspecific behavioral effects such as sedation. 
Indeed, ibudilast decreased locomotor activity at doses of 2.5 and 7.5 mg/kg and 
impaired motor coordination at 7.5 mg/kg. Supporting this, 7.5 mg/kg ibudilast 
has previously been reported to cause transient sedation and decreased reactivity 
to touch (Ledeboer et al., 2007). Therefore, the observed ibudilast-induced 
antinociception is most likely caused by sedation and impaired motor 
coordination, especially in the hot plate test. However, the mechanisms by 
which ibudilast reduces locomotor activity and impairs motor coordination are 
not known. It is unlikely that these effects are mediated through actions on glial 
cells, because they are thought not to be reactive in healthy animals. The routine 
screening of ibudilast binding to various target proteins did not reveal any target 
proteins that could mediate the decreased locomotor activity (Ledeboer et al., 
2007). In humans, however, sedation has not been reported to be a major 
problem after acute (30 mg p.o.) or subchronic (30 mg p.o. b.i.d.) administration 
regimen (Rolan et al., 2008).  
The development of morphine dependence and tolerance has been 
classically linked to the cAMP pathway (see page 25). Activation of mu-opioid 
receptors leads to the inhibition of adenylate cyclase (Sharma et al., 1975; Wang 
et al., 1994). However, repeated administration of morphine may lead to 
upregulation of adenylate cyclase, increased intracellular cAMP concentrations, 
and activation of PKA. This may contribute to the development of tolerance via 
cyclic adenosine monophosphate response element-binding protein (CREB), a 
transcription factor (Montminy and Bilezikjian, 1987) that regulates genes 
responsible for the development of physical dependence (Lane-Ladd et al., 
1997). Ibudilast, as an inhibitor of PDE, should counteract acute opioid effects 
by increasing intracellular cAMP levels. Therefore, it seems likely that the 
demonstrated effect of ibudilast is not linked to PDE inhibition in opioid 
receptor-containing neurons. In glial cells, however, the effect of PDE 
inhibition on the development of opioid tolerance may be the opposite. In an 
Alzheimer’s disease model, PDE4B, a cAMP-specific phosphodiesterase, was 
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upregulated by the administration of amyloid beta peptide leading to increased 
production of proinflammatory TNF (Sebastiani et al., 2006). After spinal cord 
injury, the PDE4 B2 isoform was upregulated from 24 h to 1 week after injury, 
at peak microglial activation (Ghosh et al., 2012). Thus, in microglial cells, the 
inhibition of PDE may lead to beneficial anti-inflammatory effects. Supporting 
this, various PDE inhibitors also show anti-inflammatory properties when 
treating peripheral diseases such as asthma and chronic obstructive pulmonary 
disease (theophylline and roflumilast; for a review, see Gavaldà and Roberts 
(2013)). An important observation, however, is that AV1013, an amino analog 
of ibudilast, shares many of the same anti-inflammatory properties as ibudilast, 
but lacks PDE inhibitory capabilities (Cho et al., 2010a). This suggests that the 
tolerance-suppressive effects of ibudilast may also result from alternative 
mechanisms, proposedly the inhibition of MIF (Cho et al., 2010a; 2010b) or 
antagonism of TLR4 receptors (Hutchinson et al., 2010b). 
6.3 Morphine combined with ultralow doses of atipamezole 
The main findings of Study II are that atipamezole, an alpha-2-adrenergic 
antagonist, had no independent antinociceptive effect at the studied ultralow 
doses, but it increased the antinociceptive effect of spinal morphine in the tail-
flick test in both morphine-naïve and morphine-tolerant rats. The 
administration of systemic atipamezole did not alter systemic morphine 
antinociception in either morphine-naïve or morphine-tolerant animals. 
Intrathecal atipamezole increased the peak antinociceptive potency of 
morphine in morphine-naïve animals, but no prolongation of the effect was 
observed. Milne et al. (2008) demonstrated that atipamezole decreased the acute 
antinociceptive effect of morphine during the first 30 minutes after 
administration, but after this period, it dramatically prolonged the 
antinociceptive response, resulting in an increase in the AUC of antinociception 
over time during 180 minutes after administration. Moreover, in morphine-
tolerant rats, the same study demonstrated a much more pronounced 
augmentation of the morphine antinociceptive effect in comparison with the 
results of Study II. Differences in experimental design might at least partly 
explain the observed differences in antinociceptive responses. In Study II, the 
optimal dose of spinal morphine was 10 times lower (1.5 µg in comparison with 
15 µg), while a 10 times higher dose of atipamezole (10 ng) was needed to 
achieve a significant augmentation of the morphine effect. Similar variation 
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between studies in the optimal dose of ultralow opioid antagonists has been 
observed (Mattioli et al., 2010). The rats in our laboratory appeared to be more 
sensitive to morphine (or more resistant to the development of acute tolerance) 
because the 15-µg morphine dose used by Milne et al. caused a long-lasting 
100% MPE (unpublished results).  
There were also several minor differences in study design. In the 
atipamezole study by Milne et al. (2008) and other reports from the same 
laboratory, morphine sulfate was used in contrast to morphine hydrochloride in 
Study II. Study II also used slightly longer tail-flick baseline response times and 
different anesthetics (ketamine vs. halothane) for the intrathecal cannulation 
operation. The intrathecal cannulation procedure itself may induce glial 
activation (DeLeo et al., 1997), and as previously noted, ketamine may have 
neuroprotective effects leading to decreased glial activation. This could also 
explain the better efficacy of morphine in our laboratory. Previously, i.t. 
morphine doses of 1 to 5 µg in 10 µl provided antinociception for several hours 
(Lemberg et al., 2008), in line with the observed responses in Study II. The best 
intrathecal morphine dose for evaluating the possible augmentative effects of 
atipamezole was 1.5 µg, resulting in approximately a 50% MPE at 30 min after 
administration. 
The mechanism by which alpha-2-adrenoceptor antagonists at doses 
considerably below those producing blockade of the alpha-2-adrenoceptor 
increase opioid antinociception is not known. One proposal is the alpha-2-
adrenoceptor-mu-opioid receptor heterodimer theory (see 2.3.4). The 
simultaneous activation of both the mu-opioid and alpha-2A-receptors in 
heterodimer complexes may change the cellular response (Jordan et al., 2003): 
activation of either mu-opioid or alpha-2A receptors leads to increased parallel 
intracellular signaling, whereas activation of both receptors decreases the 
response. An explanation for the paradoxical effect could be that the affinity of 
heterodimer-involved alpha-2-adrenoceptors for atipamezole would be greater 
than their monomeric counterparts. In the administration of ultralow doses, only 
the receptors in heterodimers would be manned, leaving the monomeric 
receptors unmanned to bind endogenic norepinephrine. However, this theory 
remains to be investigated. Interestingly, ultralow doses of opioid antagonists 
have shown similar properties to alpha-2-antagonists. For naloxone, a novel 
binding site in the cytoplasmic protein filamin A has been discovered, and it 
remains to be seen whether similar novel binding sites for alpha-2-adrenergic 
antagonists will be discovered. However, Ozdoğan et al. (2006) demonstrated 
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that morphine and especially tramadol analgesia were augmented in alpha-2A-
adrenoceptor knockout mice, a finding defending the involvement of the alpha-
2A receptor binding site in the augmentation of opioid antinociception. 
6.4 Spironolactone for the treatment of opioid tolerance 
The results of Study III indicate that spironolactone had no antinociceptive effect 
of its own in thermal models of nociception, but it dose-dependently increased the 
mean brain morphine concentration and corresponding antinociception in both 
tail-flick and hot plate tests. Spironolactone did not prevent the development of 
morphine tolerance, but in acute coadministration with morphine it restored the 
effect of morphine in tolerant rats. The peripheral µ-opioid agonist and P-gp 
substrate loperamide showed significant antinociception when combined with 
spironolactone. The results suggest that spironolactone increased the mean 
morphine brain concentration by inhibiting an efflux transporter, most likely P-gp, 
at the BBB. 
During coadministration of spironolactone, the brain:serum ratio of 
morphine was increased, indicating an increased distribution of morphine into the 
brain. Of the known BBB transporters, morphine is a substrate of P-gp (Letrent 
et al., 1999; Schinkel et al., 1995; Xie et al., 1999) and Mrp (Su and Pasternak, 
2013), transporters that move their substrates from endothelial cells to the blood 
(see 2.3.5). Spironolactone is a P-gp inhibitor (Nakamura et al., 2001), and the 
augmentation of the mean brain morphine concentration may therefore be due to 
the inhibition of P-gp. The concentrations of the substances in the spinal cord 
were not measured in the study. However, parallel results were achieved in the 
tail-flick and hot plate tests, indicating a probable increase in also the spinal cord 
concentrations of morphine. In the elimination phase, the mean serum morphine 
concentration was increased after spironolactone co-treatment, indicating a 
probable decrease in the elimination of morphine. The higher serum morphine 
concentration as well as the possible P-gp inhibition additively increased the brain 
morphine disposition, leading to enhanced and prolonged antinociception in 
spironolactone-co-treated rats. The P-gp substrate loperamide only had an 
antinociceptive effect when coadministered with spironolactone, suggesting that 
spironolactone is an effective P-gp inhibitor at the studied doses. In the study, 
however, no direct evidence for the inhibition of P-gp was shown. 
Morphine is mostly eliminated in the liver by metabolism and to a small 
extent by excretion in the kidney (Andersen et al., 2003). It is metabolized to 
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M3G by Ugt2b1 and to normorphine by CYP3A4 in humans and CYP3a1 in rats, 
and is mainly excreted in its glucuronide forms (Yaksh and Wallace, 2011). In 
spironolactone-cotreated animals, the mean M3G concentration in the liver was 
not decreased. However, it is difficult to evaluate the inhibitor effects of 
spironolactone on the Ugt2b1 enzyme, because spironolactone reduced morphine 
elimination, leading to increased morphine concentrations in the liver and thus an 
increased amount of substrate for the morphine glucuronidization reaction. In the 
presence of spironolactone, the concentration of M3G was vastly increased.   
Spironolactone had no effect by itself in acute thermal nociceptive tests. It is 
interesting, however, that intrathecal spironolactone alleviated neuropathic pain in 
the chronic compression of the dorsal root ganglion (CCD) model in rats (Sun et 
al., 2012). The spironolactone-induced antinociceptive effect in the CCD model 
was suggested to be mediated through the inhibition of activated glial cells, as the 
expression of proinflammatory cytokines and the phosphorylation of NMDA 
receptor subunit NR1 was decreased. In Study III, acute pain was measured in 
healthy animals in which glial cells are not supposed to be pathologically activated. 
Therefore, no effects of spironolactone were expected. In line with this, 
spironolactone did not have any effect on its own when the contralateral (healthy) 
paws of the animals were investigated (Sun et al., 2012). 
We examined whether spironolactone co-treatment with morphine could 
attenuate the development of tolerance. This effect could hypothetically have been 
mediated through the inhibition of M3G formation or inhibition of the 
pathological activation of glial cells. Importantly, 4-day spironolactone co-
treatment during the morphine tolerance scheme did not affect the response of an 
acute test dose of morphine. Regarding M3G, spironolactone treatment did not 
lead to the desired results, as M3G concentrations even increased as a consequence 
of decreased morphine elimination. The study did not directly evaluate the 
possible activation of glial cells, because the pharmacokinetic interaction between 
spironolactone and morphine led to vastly increased brain morphine 
concentrations in co-treated animals, rendering the comparison between the 
groups unfeasible. Analysis of glial activation would have required alterations in 
experiment design, such as the intrathecal administration of morphine or 
administration of drugs by turns in order to avoid a pharmacokinetic interaction. 
Interestingly, the development of morphine tolerance was not attenuated by 
intrathecal spironolactone (Lim et al., 2005), supporting the conclusion that the 
augmentation of the antinociceptive effect of morphine also observed in study III 
is mainly due to the increased CNS concentrations of morphine. Even though it is 
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difficult to directly extrapolate the results of animal studies to patient treatment, 
previous studies have demonstrated that inhibition of the efflux transporter P-gp 
may contribute to the effects of morphine and other opioids in humans. 
Spironolactone may be administered in high doses to patients with liver cirrhosis, 
and these patients could be exposed to respiratory depression if given morphine to 
treat pain or dyspnea. Therefore, the clinical relevance of spironolactone in co-
treatment with morphine in patients should be investigated. 
6.5 A novel pharmacokinetic interaction between morphine 
and ketamine  
Study IV demonstrated that a single dose of ketamine (10 mg/kg s.c.) did not 
cause antinociception in drug-naïve animals, but in rats under chronic morphine 
pump treatment it caused long-lasting antinociception up to 150 minutes after 
administration. At the time point of maximum antinociception, co-treatment 
caused significant increases in the brain morphine, ketamine and norketamine 
concentrations, indicating that morphine and ketamine have pharmacokinetic 
interactions during chronic morphine treatment. After two days of morphine 
withdrawal, the synergistic antinociceptive effect of ketamine and morphine in 
coadministration was still observable, but to a smaller extent. Acute co-treatment 
with ketamine and morphine in drug-naïve rats did not have such effects, 
suggesting that chronic morphine pump treatment may modify ketamine 
pharmacokinetics. 
The most prominent co-treatment-induced increases in the brain 
concentrations of morphine, ketamine, and norketamine were observed during 
chronic morphine administration, during which the increase in antinociception 
was also marked. The mean brain norketamine concentration was most notably 
elevated (3.4-fold) in morphine-tolerant rats 90 min after ketamine 
administration, and the concentration exceeded that of ketamine. Norketamine 
has been identified as a potent NMDA receptor antagonist (Ebert et al., 1997; 
Holtman et al., 2008; Shimoyama et al., 1999; see also 2.4.4), and it can 
therefore be assumed that the vastly increased brain norketamine concentration 
contributed to the increased antinociception. 
After ketamine administration to rats under chronic morphine treatment, 
the brain concentration of morphine was doubled at maximum antinociception, 
while the serum concentrations were essentially unchanged, implicating an 
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increased brain:serum ratio. Morphine is an acknowledged substrate of P-gp 
(Letrent et al., 1999; Schinkel et al., 1995; Xie et al., 1999) and possibly also Mrp 
(Su and Pasternak, 2013; see also 2.3.5), both of which are efflux proteins at the 
BBB. The inhibition of such efflux proteins by ketamine could underlie the 
decreased efflux and increased disposition of morphine in the brain. However, it is 
not known whether ketamine inhibits or is a substrate of P-gp (Doan, 2002; 
Varma et al., 2005) or Mrp. Thus, the mechanism behind the ketamine-induced 
increase in the brain:serum ratio of morphine remains undetermined.  
Ketamine increased morphine concentrations in the liver in all 
experiments. In acute coadministration, the M3G:morphine metabolic ratio was 
significantly decreased in the liver, supporting the inhibition of Ugt2b1 by 
ketamine. Furthermore, when an acute high dose of ketamine was combined 
with morphine in pilot studies, this effect was even more pronounced (Lilius et 
al., unpublished data). Indeed, ketamine has previously inhibited UGT2B7 in 
vitro (Qi et al., 2010; Uchaipichat et al., 2011). However, decreased elimination 
did not consistently lead to increased serum concentrations. Thus, the inhibition 
of efflux proteins rather than decreased metabolism may explain the increased 
brain morphine concentrations after ketamine treatment. 
Chronic morphine treatment caused a significant accumulation of 
ketamine and norketamine in the liver, serum, and brain compared with 
morphine-naïve rats. This effect was also to a lesser extent present during 
morphine withdrawal, and it was independent of an acute morphine dose. 
Similar accumulation could not be seen after acute coadministration in 
morphine-naïve animals, indicating long-term induced changes in the function 
of metabolic enzymes, transporter proteins or plasma drug carrier proteins that 
affect the pharmacokinetics of ketamine. The results did not support significant 
morphine-induced changes in ketamine metabolism. Thus, morphine tolerance-
induced ketamine accumulation could lie behind the downregulation of a 
ketamine (or its metabolite) efflux transporter, or the upregulation of a reuptake 
transporter.  
More research is needed to clarify the mechanisms of morphine tolerance-
induced changes in ketamine pharmacokinetics. These findings also imply that 
possible changes in brain concentrations of ketamine and morphine should be 
taken into account in future clinical and preclinical studies that involve the 
coadministration of these drugs. This novel pharmacokinetic drug interaction 
could explain the variation in results when treating opioid tolerance in cancer 
pain management, where high doses of morphine or other opioids are used. 
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6.6 Future perspectives 
The studies of this thesis demonstrate that tolerance to antinociceptive effects of 
systemic and intrathecal morphine develops rapidly and reliably in in vivo 
models. Opioid tolerance in animals has usually been suggested to be 
predominantly pharmacodynamic, time- and dose-dependent, and reversible 
(Collett, 1998). The first proposed mechanism for the development of tolerance 
was the upregulation of adenylyl cyclase inhibition by repeated administration of 
opioids (Collier, 1980), but tolerance has subsequently been shown to be a far 
more complex phenomenon, involving neuronal changes at both the cellular 
level and neuronal network level. In preclinical models, recent evidence has 
brought glial cells and drug transporters into the spotlight of opioid tolerance 
research.  
In the clinic, pain is difficult to study due to problems in the 
quantification of pain and pain relief, the influence of psychological factors in its 
perception, and variability in the sensitivity of individuals to pain and to opioids. 
Tolerance may often be difficult to dissociate from disease progression and/or 
opioid-induced hyperalgesia when assessing the reasons for inadequate analgesia 
and the need for escalating the opioid dose. The continuous progress in 
noninvasive imaging techniques may provide new possibilities for the study of 
glial responses in humans; for reviews, see Gerhard (2013), Inglese and Petracca 
(2013), and Obenaus (2013). 
The results of this thesis show that when two drugs are studied in 
coadministration, possible pharmacokinetic interactions must be considered, 
even when the studied drugs or drug combinations also have pharmacodynamic 
interactions. Increasing knowledge of drug transporters, their substrates, and 
potential genetic influences may aid in personalizing drug therapy and choosing 
better drug combinations while avoiding harmful ones. The pharmacokinetic 
interactions described in Studies III and IV may be advantageous, but one also 
has to be aware of potential adverse effects. An unidentified drug interaction is 
the most dangerous interaction. The undisputed advantage of animal research 
regarding pharmacokinetics is the possibility to determine the drug and 
metabolite concentrations in situ, i.e. the CNS. In humans, CNS drug 
concentrations can be estimated with pharmacokinetic modeling, whereas 
indirect radiological measurements have so far only been performed with a few 
radiolabelled drugs using fluorine magnetic resonance spectroscopy (Strauss et 
al., 1998). 
Discussion 
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The data of Studies III and IV and previous information indicate that 
spironolactone and ketamine may enhance morphine analgesia via both 
pharmacodynamic and pharmacokinetic mechanisms. NMDA antagonists have 
pharmacodynamically advantageous effects that may also indirectly affect the 
pharmacokinetics of morphine, e.g. by attenuating the upregulation of P-gp at 
the BBB, not by directly binding to the target P-gp protein but by antagonizing 
the effects of excess glutamate (Zhu and Liu, 2004), linking pharmacodynamic 
and pharmacokinetic interactions inseparably together.  
Ibudilast has already been proven safe in the treatment of asthma in Asian 
countries. Its multiple anti-inflammatory actions (inhibition of PDE and MIF 
as well as antagonism of TLR4 signaling) make it an interesting molecule for the 
treatment of various CNS diseases with inflammatory properties. It would be of 
great value to carefully analyze all the target proteins of ibudilast to fully 
understand its mechanism of action and to eliminate possibly harmful properties 
in the development of upcoming ibudilast-derived molecules.  
Almost all preclinical studies regarding opioid-induced pathological 
activation of glia have focused on morphine, the gold standard opioid agonist, 
even though the clinical use of other opioids, especially that of oxycodone, has 
increased. Thus, more attention should be paid to the basic pharmacology of 
oxycodone. The contribution of M3G, the pronociceptive metabolite of 
morphine, to glial activation warrants further study, despite the difficult 
synthesis process of the molecule (Moreira et al., personal communication). 
M3G has been suggested to be a very potent activator of the TLR4-MD2 
complex (Lewis et al., 2010), but the clinically important oxycodone and its 
metabolites have not yet been characterized in this respect. An interesting 
molecule, PTI-609 (Wang et al., 2012a), combines opioid receptor agonism 
with the inhibition of  TLR4-MD2 signaling by binding to filamin A, an 
intracellular cytoskeleton protein (Burns and Wang, 2010). The development of 
new molecules with such properties may allow the positive analgesic actions of 
mu-opioid receptor activation while avoiding pronociceptive xenobiotic-induced 
central immune signaling. 
Ultralow doses of various alpha-2-adrenoceptor antagonists and opioid 
receptor antagonists have shown promise for the treatment of acute opioid 
antinociception and also tolerance (Table 2, page 42). As a nonselective alpha-2-
adrenoceptor antagonist, atipamezole is not ideal for dissecting the 
pharmacology behind the phenomenon, but on the other hand, its pharmacology 
is rather well characterized in veterinary medicine and also in human studies. 
Discussion 
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More research is needed to understand the role of dimerization of alpha-2-
adrenoceptors and opioid receptors in opioid analgesia, bearing in mind the 
possibility of other novel binding sites for alpha-2-antagonists. 
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CONCLUSIONS 
The conclusions for the specific aims set in Aims of the study are as follows: 
 
I. Acutely administered ibudilast decreased spontaneous locomotion and 
impaired motor coordination. Ibudilast did not inhibit the 
development of opioid tolerance, but it restored the antinociceptive 
effect of morphine in morphine-tolerant animals after single and 
repeated administration. It did not prevent the development of opioid 
tolerance in a four-day tolerance model. 
 
II. When administered subcutaneously, ultralow doses of atipamezole 
failed to augment morphine antinociception in acute administration or 
in morphine tolerance. In intrathecal administration, ultralow 
nanogram-scale doses of atipamezole augmented morphine 
antinociception both acutely and in morphine tolerance.  
 
III. Spironolactone dose-dependently increased the antinociceptive effect 
of morphine. The effect was mediated via increased concentrations of 
morphine in the CNS. Spironolactone did not inhibit the development 
of the pronociceptive morphine metabolite M3G, and it did not 
prevent the development of opioid tolerance. Loperamide, the 
peripheral opioid and P-gp substrate, showed antinociceptive 
properties when coadministered with spironolactone. 
 
IV. In acute cotreatment, a small dose of ketamine increased the brain 
access of morphine only marginally, whereas the same dose of 
ketamine administered to rats under chronic morphine treatment led 
to markedly increased brain concentrations of morphine, ketamine, 
and norketamine compared to the situation in which the drugs were 
administered alone. Moreover, chronic morphine treatment caused 
increased accumulation of ketamine, particularly in the liver.  
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